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Zusammenfassung
Die Expression von „high-risk“ HPV-16 E7 in einer Zelle ohne HPV-16 E6 führt
zur Degradation von pRB, aber auch zur Stabilisierung von p53. Dieser Anstieg wird
nicht durch verstärkte Transkription, sondern durch eine verlängerte Halbwertszeit des
p53 Proteins bewirkt (Jones and Munger, 1997). Die Ergebnisse dieser Arbeit
verdeutlichen, dass das stabilisierte p53 in HPV-16 E7-expremierenden Zellen weder in
der Präsenz, noch beim Fehlen von Wachstumsfaktoren als Transkriptionsfaktor aktiv ist,
obwohl p53 eine Rolle in der HPV-16 E7 vermittelten Apoptose durch
Wachstumsfaktorentzug zu spielen scheint. Außerdem kann das stabilisierte p53 in HPV-
16 E7 expremierenden Zellen mdm2 binden, befindet sich in einer Wild-Typ
Konformation und ist im normalen Zellkompartment lokalisiert. Weder der nukleäre
Export von p53, noch seine Degradation durch das Proteasom wird von HPV-16 E7
verhindert. Es bleibt zu untersuchen, ob HPV-16 E7 das Zusammensetzen des p53
Transkriptions-Initiations-Komplexes oder die Ubiquitinierung von p53 inhibiert und p53
dadurch stabilisiert und inaktiviert
Vorhergehende Studien zeigten, dass Zellen, die Oncogene, wie z.B. HPV-16 E7
expremieren, unter suboptimalen Wachstumsbedingungen prädestiniert Apoptose zu
begehen. Untersuchungen der molekularen Mechanismen dieser HPV-16 E7 abhängigen
Apoptose durch Wachstumsfaktorentzug zeigten die Involvierung des Mitochondriums
anhand von Messungen der Cytochrom C Freisetzung und der Caspase 3 Aktivierung,.
Der Apoptose-Induzierende Faktor (AIF) verlässt das Mitochondrium nicht und scheint
deshalb nicht in die HPV-16 E7 vermittelte Apoptose verwickelt zu sein. Es wurde eine
verstärkte Expression von IGFBP-2 und IGFBP-5 in HPV-16 E7-expremierenden
proliferierenden Zellen beobachtet. Die Expression dieser beiden Proteine steigt nach
Wachstumsfaktorentzug weiter an. Es wurde zuvor berichtet, dass diese Proteine den
Wachstumsfaktor IGF-I binden können und seine Verfügbarkeit für die Zelle regulieren.
Bislang ist unklar, ob die Expression dieser beiden Proteine HPV-16 E7-expremierende
Zellen für Apoptose prädestiniert oder ob dies eine antiapoptotische Antwort der Zelle
auf den Wachstumsfaktorentzug darstellt
Zusammenfassung                                                                                                                                                
Die Ergebnisse dieser Arbeit tragen zum besseren Verständnis bei, wie
Wirtszellen auf die, durch virale Oncoproteine induzierte Deregulation des Zellzykluses
und die nachfolgende, unkontrollierte Proliferation reagieren. Detailliertes Wissen über
die Effekte von HPV-16 E7 sowohl auf proliferierende als auch auf unter
Wachstumsfaktorentzug kultivierten Zellen könnte zur Entwicklung neuartiger
Behandlungsmethode von HPV-positiven Krebsarten führen, indem man die Zellen
anfällig für HPV-16 E7 vermittelte Apoptose macht.
Schlagworte: Tumor Suppressor p53, Human Papillomavirus Typ 16 E7 Oncoprotein,
Apoptose
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1. Repeatedly used abbreviations
AIF apoptosis inducing factor
CKI cyclin-dependent kinase inhibitor
E6AP E6 associating protein
HFK human foreskin keratinocyte
HPV human papillomavirus
IFN interferon
IGF insulin-like growth factor
IGFBP insulin-like growth factor binding protein
Ik B inhibitor of NFk B
NF k B nuclear factor kappa B
ORF open reading frame
p53DD carboxyl terminal truncation mutant of p53
pRB retinoblastoma tumor suppressor protein
TAF TBP-associated factor
TBP TATA-binding protein
TF transcription factor
TGF- b transforming growth factor beta
TNFR TNF receptor
TNF- a tumor necrosis factor alpha
TRAIL TNF-related apoptosis inducing ligand
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2. Introduction
2.1 Papillomaviruses
Papillomaviruses are widespread and have been isolated from different vertebrate
species including cattle, birds, deer, mice and humans. Although papillomaviruses
isolated from these various species are quite similar, they show a high degree of species
specificity, which means that a papillomavirus isolated from one species does not cause a
productive infection in a second species. In addition, papillomaviruses exhibit a specific
tropism for squamous epithelial cells. Papillomavirus infections cause lesions at either
cutaneous or mucosal sites of the genital tract, oral pharynx or esophagus. The productive
infection of cells by papillomaviruses can be divided into early and late phases, which are
linked to the differentiation state of the infected epithelial cell (Fig. 1). Because the basal
cell is
Figure 1:  The differentiation state of the host cell and the viral life cycle are tightly linked. To induce a
persistent infection, HPV infects the basal cell. Viral DNA replication, late gene expression and virion
assembly occurs in the differentiating cells.
the only cell in the squamous epithelium that is capable of dividing, the virus must infect
the basal cell to induce a lesion that can persist. Late gene expression, synthesis of capsid
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proteins, viral DNA synthesis, and assembly of virions occur only in terminally
differentiating squamous epithelial cells (Fig. 1). A persistent papillomavirus infection
usually results in epithelial hyperplasias, also referred to as warts.
Papillomaviruses are non-enveloped viruses with double-stranded circular DNA
genomes of about 8000 base pairs. The approximately 10 designated open reading frames
(ORFs) of the virus genome are all encoded on one DNA strand. These ORFs are
classified into early or late ORFs. The numbers of the early (E1-8) and late (L1 and L2)
ORFs reflect their sizes (Fig. 2). The terms “late” and “early” ORFs reflect the time of
their expression during the viral life cycle. The virus genome also contains a non-coding
long control region (LCR), which contains the origin of replication and the constitutive
transcriptional enhancer sequence as well as the viral E2 responsive enhancer (Fig. 2).
Figure 2: HPV genome structure. The HPV-16 genome consists of a double stranded DNA genome of
7905 basepairs and encodes early and late genes. The early genes (E) encode proteins that are necessary for
viral replication during the early viral life cycle, while late genes (L) encode viral capsid proteins that are
expressed later in viral life cycle. The long control region (LCR) is a non-coding DNA sequence that
controls viral replication and transcription.
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2.1.1 Human Papillomaviruses
The continually growing list of human papillomaviruses (HPVs) now comprises
more than 100 distinct types. Like all papillomaviruses, HPVs possess a pronounced
tropism for squamous epithelial cells. Despite their similar overall genomic make-up,
different HPVs infect epithelia at specific anatomic locations. Approximately 30 HPV
types preferentially infect the anogenital tract mucosa. These HPVs can also be detected
in the oral mucosa, and are further classified into ‘high-risk’ and ‘low-risk’ types based
on the clinical prognosis of the lesions that they cause. Low-risk HPVs are associated
with benign warts, whereas high-risk HPVs cause lesions that have a propensity for
carcinogenic progression. Even though the rate of carcinogenic progression is relatively
low, infections with high-risk HPVs account for almost all human cervical cancers, a
leading cause of cancer in younger women worldwide (reviewed in zur Hausen, 1996)).
Moreover, approximately 20% of oral cancers, particularly oropharyngeal carcinomas in
patients that lack risk factors such as alcohol and tobacco abuse, are also associated with
high-risk HPVs (Gillison et al., 2000).
Figure 3:  HPV genome integration. Integration of the HPV genome into a host chromosome often results
in the disruption of the E2 gene. E2 is a negative regulator of E6 and E7 expression, and the loss of E2
results in the constitutive expression of the two viral oncoproteins. Constitutive E6/E7 expression
contributes to the carcinogenic progression of a cell. E6 and E7 are transcribed from a single promoter
(P97). The minimal HPV segment retained in cervical cancer, consisting of the LCR and the E6 and E7
genes, is indicated by a black bar.
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During carcinogenic progression of a high-risk HPV infected cell, the viral
genome frequently integrates into the host chromosome. This event is quite random with
respect to the host chromosome but follows a specific pattern with respect to the viral
genome. As a consequence of integration, expression of two early genes (E6 and E7)
becomes dysregulated due to the frequent disruption of the gene that encodes the viral
transcription factor E2 (Fig. 3), a negative regulator of the E6 and E7 promoter. The E6
and E7 proteins of the high-risk HPVs have oncogenic activities. E7 functionally
inactivates the retinoblastoma tumor suppressor protein (pRB) and the related “pocket
proteins” p107 and p130 by destabilization (Boyer et al., 1996; Dyson, 1998; Gonzalez et
al., 2001; Jones and Münger, 1997), while E6 protein binds to (Werness et al., 1990) and
promotes the degradation of the tumor suppressor p53 (Scheffner et al., 1990).
Expression of high-risk HPV E6 and E7 results in the extension of the life span and
immortalization of normal human genital epithelial cells, the normal host cell type of
these viruses (Hawley-Nelson et al., 1989; Hudson et al., 1990; Münger et al., 1989).
Moreover, continuous expression of E6 and E7 in cervical cancer cell lines is required for
the maintenance of the transformed state (Goodwin and DiMaio, 2000; Wells et al.,
2000).
2.1.2 The HPV E7 oncogene
HPV E7 was the first oncogene of high-risk HPVs to be discovered. HPV E7
induces transformation of rodent fibroblast cell lines (Bedell et al., 1989; Phelps et al.,
1988; Vousden et al., 1988; Yasumoto et al., 1986) and can cooperate with the ras
oncogene to transform primary rodent fibroblasts (Matlashewski et al., 1987; Phelps et
al., 1988). HPV E7 proteins are phosphoproteins (Smotkin and Wettstein, 1987)
composed of approximately 100 amino acid residues that contain two casein kinase II
consensus phosphorylation sites (Barbosa et al., 1990) as well as another site for an
unknown protein kinase (Massimi and Banks, 2000). They contain a LxCxE motif at the
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Figure 4:  Schematic structure of the HPV-16 E7 oncoprotein. The two conserved regions (CR1 and CR2)
at the amino-terminus are involved in transformation. CR2 also contains a LxCxE motif, which represents
the core binding site for pRB and the related pocket proteins p130 and p107. A metal binding domain at the
carboxyl-terminus consists of two copies of a Cys-X-X-Cys sequence motif can act as a dimerization or
multimerization domain and influences protein stability and disruption of pRB/E2F1complexes.
amino terminus, which represents the core binding site for pRB and the related pocket
proteins p130 and p107 (Fig. 4). A zinc-binding domain consisting of two copies of a
Cys-X-X-Cys sequence motif separated by 29 amino acid residues in the carboxyl
terminus (Barbosa et al., 1989; McIntyre et al., 1993) can act as a
dimerization/multimerization domain (Clemens et al., 1995; Clements et al., 2000;
McIntyre et al., 1993) (Fig. 4). Immunofluorescence studies have shown that HPV E7
proteins are predominantly nuclear (Greenfield et al., 1991; Sato et al., 1989). A number
of non-nuclear cellular target proteins of E7 have been described in recent years
(reviewed in Zwerschke and Jansen-Durr, 2000) and hence it is possible that at least
under some conditions, a certain fraction of E7 may reside in the cytoplasm (Smotkin and
Wettstein, 1987). E7 has also been detected at nucleolar structures in some cell types
(Zatsepina et al., 1997). It has a relatively short half-life, which results in low cellular
steady-state levels (Smotkin and Wettstein, 1987). HPV-16 E7 is a target of ubiquitin-
dependent proteolysis through a rather uncommon mechanism that involves conjugation
of ubiquitin mojeties to the amino terminal methionine residue (Reinstein et al., 2000).
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HPV E7 can uncouple differentiation and proliferation and hence, retain
differentiating keratinocytes in a DNA replication competent state (Cheng et al., 1995;
Woodworth et al., 1992). Several studies in mouse and human keratinocytes have shown
that like in other cell types (Guo et al., 1995; Steinman et al., 1994), p21CIP1 plays an
important role in coupling cell cycle arrest and differentiation in keratinocytes (Alani et
al., 1998; Di Cunto et al., 1998; Missero et al., 1996). The steady state levels of p21CIP1
increase during cellular differentiation resulting in inactivation of cdk2 activity and
growth arrest. The inhibitory activities of cyclin dependent kinase inhibitors (CKIs) such
as p21CIP1 and p27KIP1 can be abrogated by HPV E7 (Funk et al., 1997; Jones et al.,
1997a; Zerfass-Thome et al., 1996). The retinoblastoma tumor suppressor and the related
‘pocket proteins’ p107 and p130 are major cellular targets of high-risk HPV E7 proteins.
High-risk HPV E7 proteins induce the proteolytic elimination of the pRB family
members (Boyer et al., 1996; Gonzalez et al. , 2001). This ability to inhibit CKIs and to
destabilize the pocket proteins and the subsequent activation of E2F results in enhanced
expression of cellular proteins that are rate-limiting for cellular DNA synthesis and
contribute to the function of E7 as a viral replication competence factor. Consistent with
this notion, it was shown that expression of E7 and its ability to subvert cellular targets
such as pRB are indispensable for HPV replication and the full viral life cycle (Flores et
al., 2000; Thomas et al., 1999).
High-risk HPV E7 interferes with additional regulatory pathways of a normal cell
to guarantee the continued proliferation of the infected cell. It can abrogate the cytostatic
activities of cytokines such as the transforming growth factor beta (TGF-b)  (Pietenpol et
al., 1990) and tumor necrosis factor alpha (TNF-a ) (Basile et al., 2001), and severely
compromise cellular signaling by interferon (IFN) (Barnard and McMillan, 1999;
Barnard et al., 2000; Park et al., 2000; Perea et al., 2000). It has also been reported that
HPV E7 interacts with the 110 kDa TBP-associated factor (TAF110) which may
contribute to the ability of E7 to modulate transcription (Mazzarelli et al., 1995). In
addition, E7 was reported to interact with the insulin-like growth factor binding protein-3
(IGFBP-3), a protein that is involved in negatively regulating the cellular availability of
the important cellular survival factors, insulin-like growth factors (IGFs) (Mannhardt et
al., 2000). IGFBP-3 is a proapoptotic protein (Rajah et al., 1997) that is regulated by p53
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(Buckbinder et al., 1995) and thereby involved in p53 dependent apoptosis (Hollowood et
al., 2000).
Furthermore, cells expressing high-risk HPV E7 have an altered cellular
metabolism including decreased glycolytic flux (Mazurek et al., 2001; Zwerschke et al.,
1999) and lowered intracellular glycogen stores (Zwerschke et al., 2000). These effects
may drive cellular hyperproliferation or represent a consequence of the altered energy
requirements of rapidly growing transformed cells. An additional physiological hallmark
of cells transformed by HPV E7 is an increase of the intracellular pH by stimulation of
Na+/H+ exchanger activity. Intracellular alkalinization is thought to represent an early and
important step that contributes to cellular transformation (Reshkin et al., 2000).
HPV E7 plays a role in carcinogenic progression by inducing genomic instability
(Kessis et al., 1996; Thomas and Laimins, 1998; White et al., 1994). HPV E7 expressing
cells were found to be polyploid or aneuploid (Duensing et al., 2000; Hashida and
Yasumoto, 1991) (Southern et al., 2001). Aneuploidy is generated by the gain or loss of
chromosomes as a consequence of non-symmetrical chromosome segregation during cell
division and is frequently observed in tumor cells. Recent studies have shown that HPV-
16 E7 can interfere with the ordered synthesis of centrosomes (Duensing et al., 2001;
Duensing et al., 2000), the major microtubule organizing centers during mitosis
(reviewed in Murray, 2001).
2.2 The effects of viral oncogenes on the tumor suppressors p53 and
pRB
2.2.1 The tumor suppressor p53
The p53 gene encodes a protein composed of 393 amino acids that functions as a
transcription factor. It contains five highly conserved regions, termed domains I-V that
are crucial for p53 functions (Soussi et al., 1990; Soussi et al., 1987; Soussi and May,
1996) and represent "hot spot" areas for mutations. Structure function analyses have
identified four major functional domains: An amino terminal transcriptional activation
domain (amino acids 1-42), a central sequence-specific DNA-binding domain (amino
acids 102-292), an oligomerization domain (amino acids 323-356) and a regulatory
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domain (amino acids 360-393) in the carboxyl terminal portion (reviewed in Levine,
1997) (Fig. 5). The amino terminal transcriptional activation domain of p53 is acidic and
allows p53 to recruit the basal transcriptional machinery, including the TATA-box
binding protein (TBP) and the TBP-associated factors (TAFs) 40 and 60, which are
components of TFIIH (Lu and Levine, 1995; Thut et al., 1995). The central DNA binding
region of p53 contains the four conserved domains II-V, where 80-90 % of the mutations
associated with human tumors are clustered. This part of the protein recognizes and binds
a consensus DNA sequence which consists of two copies of the 10 base-pair motif 5’-
PuPuPu-C(A/T)(T/A)G-PyPyPy-3’ separated by 0-13 nucleotides (el-Deiry et al., 1992).
The C-terminal region contains a tetramerization domain and a basic region. The
tetramerization of p53 (Kraiss et al. , 1988) via its oligomerization domain (Clore et al. ,
1994) (Jeffrey et al., 1995) is required for efficient transactivation in vivo and for p53-
mediated growth suppression (Pietenpol et al., 1994). The basic region acts as a negative
regulator of sequence specific DNA binding (Wang et al., 1996; Wang and Prives, 1995)
(Fig. 5).
Figure 5:  Schematic p53 structure. Roman numerals represent the five regions of p53 that are conserved
within p53 from all vertebrates and are mutational “hot spots”. Known phosphorylation (P) and acetylation
(Ac) sites are indicated as well as their known modifiers. Shown below and indicated by red horizontal bars
are the 4 functional domains while blue bars indicate various domains important for biological activities
and p53-protein complex formation. See text for details.
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In normal cells, p53 is present at extremely low levels because the protein is
rapidly degraded following synthesis (Kubbutat and Vousden, 1998). Degradation of p53
is mediated by a large multiprotease complex, the 26S proteasome and is dependent on
ubiquitination. The E3 ubiquitin ligase marking p53 for degradation is mdm2 (Honda et
al., 1997), a transcriptional target of p53 (Barak et al., 1993). The mdm2 protein interacts
with the amino terminal transcriptional activation domain of p53 and inhibits its
transcriptional function (Oliner et al., 1993).  The importance of mdm2 as a regulator of
p53 became apparent when mdm2-deficient mice showed very early embryonic lethality
and the simultaneous deletion of p53 completely rescued this phenotype (Jones et al.,
1995; Montes de Oca Luna et al., 1995).
The p53 protein plays an important role in the suppression of tumorigenesis. The
p53 gene is deleted or contains point mutations in approximately 60% of all human
cancers (Baker et al., 1989; Baker et al., 1990; Caron de Fromentel and Soussi, 1992;
Hollstein et al., 1994; Hollstein et al., 1996; Marshall, 1991; Nigro et al., 1989). Wild
type p53 is believed to guard the integrity of the cellular genome (Lane, 1992) by
inhibiting cell cycle progression or inducing apoptosis in response to aberrant
proliferation signals, DNA damage or cellular stress. It acts as a key regulator of a
complex circuitry involving mdm2, p14ARF and other cellular proteins (Freedman and
Levine, 1999; Sherr, 1998), that link the pRB pathway to the p53 pathway. Upon the
hyperphosphorylation or the loss of pRB, E2F is released. p14ARF is a transcriptional
target of E2F and the upregulation of p14ARF levels results in the inhibition of mdm2
(Stott et al., 1998) and subsequent stabilization and activation of p53 (Chin et al., 1998),
which induces either growth arrest or apoptosis in response to deregulation of pRB
function (reviewed in May and May, 1999).
Rapid degradation of p53 in normal cells is critical to tightly regulate p53 activity.
Cellular stress, such as DNA damage, heat shock, hypoxia, oncogene activation,
metabolic changes and pH alterations can all result in the stabilization and activation of
p53. This is due to posttranslational modifications such as phosphorylation and
acetylation in the amino terminal and carboxyl terminal regions of p53. The protein
kinases ATM and ATR become activated upon DNA damage and phosphorylate p53 at
serine 15 and serine 37 in its amino terminus (Canman et al., 1998; Chehab et al., 1999;
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Tibbetts et al., 1999), which disrupts the interaction of mdm2 with p53. This causes p53
stabilization and enhances its DNA binding activity. The stabilized p53 becomes
activated as a transcription factor by acetylation of the lysine residues 320 and 382 at its
carboxyl terminus (Gu and Roeder, 1997; Sakaguchi et al., 1998). This leads to the
induction of target genes that mediate either growth arrest or apoptosis (reviewed in
Meek, 1999).
2.2.2 The retinoblastoma tumor suppressor (pRB)
The retinoblastoma tumor suppressor protein (pRB) is a nuclear phosphoprotein
that contains two conserved domains A and B, also called the A/B pocket. This pocket
domain is involved in protein-protein interactions. The transforming proteins of different
DNA tumor viruses, namely Ad E1A, SV40 TAg and HPV-16 E7 all bind this domain
and thereby inactivate pRB. This domain is also involved in E2F binding. pRB as well as
the other members of the “pocket protein” family, p107 and p130, act as important
regulatory subunits of E2F transcription factor complexes. E2F transcription factors are
heterodimers consisting of an E2F subunit bound to a member of the “dimerization
partner” family (DP) (Bandara et al., 1993; Helin et al., 1993). E2F/DP complexes are
critical regulators of many genes that are rate limiting for entry into S phase. Binding of
hypophosphorylated pocket proteins to the E2F/DP complexes masks their transcriptional
activation domain and since  encodes a transcriptional repressor domain, pRB binding
converts E2F/DP complexes into transcriptional repressors that actively prevent S phase
entry (Luo et al., 1998; Weintraub et al., 1995; Weintraub et al., 1992). Upon cdk-
dependent phosphorylation of pRB in late G1-phase, these complexes dissociate and E2F
complexes are converted into transcriptional activators that stimulate S phase entry. The
G1/S phase transition is tightly regulated by pRB through this mechanism.
2.2.3 Viral oncoproteins and the tumor suppressor p53 and pRB
Several DNA tumor viruses such as Adenoviruses and SV40 encode oncoproteins
that target both p53 and pRB. The binding of viral oncoproteins to the cellular tumor
suppressor proteins p53 and pRB is fundamental to the induction of S-phase in host cells
by the small DNA tumor viruses to ensure viral replication (Nevins, 2001). The induction
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of S-phase in differentiating cells is crucial to viral replication since epithelial cells
withdraw from the cell cycle during differentiation and stop expressing enzymes that are
necessary for DNA replication. Viruses had to evolve mechanisms to guarantee
expression of S-phase genes of the host cell to ensure the availability of these rate-
limiting proteins for their own replication. In a cell infected with high-risk HPV, the E7
oncoprotein inactivates pRB and the related proteins p107 and p130 by inducing their
destabilization by ubiquitin mediated degradation (reviewed in Munger et al., 2001)
which causes the release of active E2F transcription factors. The free transcription factor
E2F induces the transcription of a set of S-phase genes like DNA polymerase-a ,
dihydrofolate reductase (DHFR), thymidine kinase (TK), that are rate limiting for DNA
synthesis. Activation of E2F allows the virus to establish a replication competent cellular
milieu in differentiated keratinocytes that are normally terminally withdrawn from the
cell cycle.
High levels of E2F can also result in the inhibition of mdm2 through p14ARF. The
p14ARF protein binds to mdm2 and inhibits the transfer of ubiquitin to p53. This results in
subsequent stabilization and activation of p53. To prevent p53 from inducing growth
arrest or apoptosis of an HPV infected cell, the HPV E6 protein binds to and promotes
the degradation of the tumor suppressor p53 (Scheffner et al., 1990; Werness et al.,
1990). E6 functions together with the cellular protein E6AP as a ubiquitin ligase and
marks p53 for ubiquitin mediated degradation through the 26S proteasome (Rolfe et al.,
1995). The inactivation of p53 allows cells inappropriately stimulated by free E2F to
circumvent these p53 checkpoints, enter S-phase and replicate viral DNA (Fig. 6). This
inactivation of the two tumor suppressors pRB and p53 in a high-risk HPV-infected cell
results in the uncontrolled proliferation of the cells and may contribute to subsequent
development of malignant tumors.
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Figure 6: Effects of HPV E6 and HPV E7 on the cell cycle. Positive (green arrows) and negative (red bars)
effects are shown. The degradation of p53 by HPV E6 and the destabilization of pRB and inactivation of
p21CIP1 by HPV E7 result in uncontrolled transition from G1- to S-phase and progression through the cell
cycle. The negative impact of HPV E7 on p53 function is the subject of this thesis.
2.2.4 The HPV E7 oncogene and the tumor suppressor p53
HPV E7 can interfere with the ability of p53 to induce G1 growth arrest in
response to cellular insults (Demers et al., 1994a; Hickman et al., 1994; Slebos et al.,
1994; Vousden et al., 1993). Multiple mechanisms likely contribute to this activity of E7,
including E2F-mediated aberrant expression of cyclins E and A (Hickman et al., 1997)
and cdc25A (Katich et al., 2001), inactivation of the p53-responsive CKI p21CIP1 (Funk et
al., 1997; Jones et al., 1997a) and the decreased cellular steady-state levels of pRB (Jones
and Münger, 1997). It was shown previously that HPV E7 expressing cells contain
increased steady-state levels of p53 (Demers et al., 1994b) due to an extended half-life of
HPV E6 p53 
cyclin/cdk
pRB-E2F 
E2F 
HPV E7 
p21CIP1 
Apoptosis 
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p53, suggesting that E7 may perturb p53 degradation (Jones and Münger, 1997). It was
reported that the p53-specific ubiquitin ligase mdm2 is not as efficiently bound to p53 in
E7 expressing cells as in normal cells (Seavey et al., 1999). Given the ability of E7 to
activate E2F-responsive promoters (Phelps et al., 1991), it has been postulated that the
increased p53 levels in E7 expressing cells may be due to E2F-mediated transcriptional
induction of p14ARF (Bates et al., 1998), an inhibitor of mdm2-dependent p53 degradation
(Stott et al., 1998; Zhang et al., 1998). Interestingly, however, expression of E7 does not
cause a rapid increase of p14ARF, and stabilization of p53 by E7 is also observed in mouse
embryo fibroblasts that lack p19ARF, the murine homolog of the human p14ARF (Seavey et
al., 1999). These results suggest that alternative mechanisms contribute to the ability of
E7 to stabilize p53. Nevertheless, it has been demonstrated that the normal physiological
pathway of mdm2-mediated p53 turnover is not active in high-risk HPV E6/E7
expressing cervical carcinoma cell lines and the rapid turnover of p53 in these cell lines is
solely a function of the E6/E6AP p53-specific ubiquitin ligase complex (Hengstermann et
al., 2001)
The steady-state levels of the CKI p21CIP1, a transcriptional target of p53, are
increased in E7 expressing cells just as p53 levels are (Demers et al., 1994a; Thomas and
Laimins, 1998). This increase, however, is mostly a consequence of protein stabilization
and is not due to transcriptional induction by p53 (Jones et al., 1999; Noya et al., 2001).
In fact, it appears that despite its increased levels, the transcriptional activity of p53 is
disturbed in E7 expressing cells. Consistent with this finding, it was shown that E7 could
interfere with the activation of p53-responsive reporter constructs in transient transfection
assays (Massimi and Banks, 1997). This has been linked to the ability of E7 to interact
with TBP (Massimi and Banks, 1997; Phillips and Vousden, 1997).
Previous studies indicate that in E7 expressing cells, p53 is activated upon DNA
damage to a comparable extent as in control cells (Jones et al., 1999). This indicates that
the p53 in E7 expressing cells retains the ability to be functionally activated upon specific
stimuli.
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2.3 Viral oncoproteins predispose cells to apoptosis upon cellular stress
2.3.1 Programmed cell death or apoptosis
Apoptosis, or programmed cell death, is a process required for development and
maintenance of metazoan organisms. In normal cells apoptotic cell death is tightly linked
to cell proliferation and leads to the regulated turnover of cells, which is crucial to the
preservation and function of organisms. Defects in cell death pathways, or uncoupling of
cell death and proliferation, can lead to developmental abnormalities and importantly
contribute to the pathogenesis of degenerative and neoplastic diseases (reviewed in
Zornig et al., 2001). Apoptosis also eliminates aberrant cells created by cellular stress
such as DNA damage, hypoxia or viral infection. Cells undergoing apoptosis show highly
characteristic morphological changes including chromatin condensation, DNA
fragmentation, membrane blebbing, cell shrinkage, and compartmentalization of the dead
cells into membrane-enclosed vesicles or apoptotic bodies (Kerr et al., 1972;
Oberhammer et al., 1993; Wyllie, 1980). Survival factors prevent normal cells from
undergoing apoptosis unless they receive specific genotoxic signals like DNA damage or
viral infection, which can lead to the initiation of death pathways.
Apoptosis is mediated by the sequential activation of caspases, a family of cysteine
proteases with specificity for aspartate residues in their target substrates. Caspases are
constitutively produced in most cells as inactive monomeric proenzymes and are
activated by specific proteolytic cleavage and assembly into tetramers (Green and
Kroemer, 1998). Caspases have the capacity to activate each other and co-operate in an
intracellular cascade leading to the activation of downstream ‘effector’ caspases, such as
caspase-3, -6 and –7. Engagement of effector caspases is a key event that commits the
cell to the cleavage of substrates which results in the typical morphological changes of
apoptosis and the degradation of chromosomal DNA (Enari et al., 1998). At least two
pathways converge on the activation of caspase-3. These pathways were previously
thought to be independent, but are now known to interact in a cell-specific manner (Li et
al., 1998). The first pathway is initiated by internal cellular stress such as DNA damage
and is mostly mediated by mitochondria, which play a central role in regulating cell death
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Figure 7: Overview of apoptotic signaling pathways. Pro-apoptotic stimuli include the activation of cell
death receptors by their ligands (FasL, TNF) and DNA damage. The binding of Fas or TNF to their
receptor activates the initiator caspases 8 and 10, while DNA damage leads to the activation of p53 and the
subsequent activation of the initiator caspase 9. Once activated, these caspases cleave and activate
downstream effector caspases (including caspase 3, 6 and 7) which in turn induce apoptosis. Cytochrome c
released from mitochondria is coupled to the activation of caspase 9, a key initiator caspase. Survival
factors including growth factors that activate Akt thereby inhibit Bad and prevent cytochrome c release.
and is mostly mediated by mitochondria, which play a central role in regulating cell death
(Green and Reed, 1998; Kroemer and Reed, 2000). In response to apoptotic stimuli
cytochrome c is released from the mitochondria, forms a complex with Apaf-1 and
procaspase 9 and this complex, the apoptosome, converts procaspase 9 into its active
form (Li et al., 1997; Zou et al., 1999). Activated caspase 9 cleaves downstream caspases
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including caspase 3. The second pathway is induced by the activation of the initiator
caspases, caspase-8 and –10 upon ligation of cytotoxic cytokines such as TNF-a , Fas
ligand or TRAIL to death domain receptors at the cell surface. Activated caspase-8 then
acts directly on caspase-3 to initiate apoptosis (Kroemer and Reed, 2000) (Fig. 7). There
is some crosstalk between these two pathways. One molecule that connects the two
pathways is Bid. Bid is a cytoplasmic protein that is cleaved by activated caspase 8 or 10.
The cleaved Bid translocates to the mitochondria where it induces cytochrome c release
and triggers an apoptotic response (Gross et al., 1999).
The tumor suppressor p53 can induce apoptosis in response to cellular stress such
as DNA damage. Under such conditions p53 is stabilized and activated as a transcription
factor. This results in the transcriptional induction of apoptosis mediating target genes
including bax or IGFBP-3 (reviewed in Meek, 1999). Bax is a proapoptotic member of
the Bcl-2 family of mitochondrial apoptosis regulators. It can counteract the death
suppressive activity of the antiapoptotic family members Bcl-2 or Bcl-xL (reviewed in
Korsmeyer, 1999). IGFBP-3 is regulated by p53 as well (Buckbinder et al., 1995) and
was shown to play a role in p53 dependent apoptosis (Rajah et al., 1997). IGFBP-3 was
reported to suppress proliferation and induce apoptosis (reviewed in Oh et al., 1995) by
negatively regulating the availability of the growth factor IGF-I to its receptor (Binoux,
1996). It was also reported to be involved in senescence (Goldstein et al., 1991;
Grigoriev et al., 1995). Other p53 target genes like PERP, Noxa and p53AIP1 are
involved in p53 mediated apoptosis as well (Attardi et al., 2000; Oda et al., 2000a; Oda et
al., 2000b). Various other genes induced during p53 dependent apoptosis were identified
by serial analysis of gene expression (SAGE). These p53-inducible genes (PIGs) were
predicted to encode proteins involved in the cellular response to oxidative stress (Polyak
et al., 1997).
p53 induces apoptosis not only through transcription-dependent but also through
transcription-independent mechanisms. The transcription-independent mechanisms of
p53-mediated apoptosis are not very well studied. However it was reported to be
dependent on caspase 8 activity (Ding et al. , 2000) as well as on protein phosphatase 1
and 2A activity (Yan et al., 1997). Another report showed that p53 can induce
relocalization of the cytokine receptor Fas from the Golgi to the cell surface, thereby
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rendering a cell more prone to apoptosis (Bennett et al., 1998). p53 may also contribute
to apoptosis by directly signaling to the mitochondria when a small fraction of stress-
induced p53 protein traffics to the mitochondria where it induces the release of
cytochrome c and subsequent activation of caspase 3 (Marchenko et al., 2000).
2.3.2 Viruses and apoptosis
In addition to its role in tissue homeostasis and development, apoptosis is an
essential component of the cellular response to injury (Thompson, 1995). In particular,
many cells will undergo programmed cell death following viral infection. Many viruses
take advantage of host cell-mediated apoptosis while finishing the infectious cycle. Death
of the host cell by apoptosis offers several advantages for the virus. During apoptosis the
entire cellular content, including progeny virus, is packaged into membrane-bound
apoptotic bodies that are rapidly taken up by surrounding cells. This limits the
inflammatory response and allows the infection to spread undetected by the host
organism. Virus particles enclosed within apoptotic vesicles are also protected from
inactivation by host antibodies and proteases.
Viruses have also developed a range of strategies to prevent elimination of the
infected host cell by the host immune response. These strategies include the inhibition of
the interferon response as well as the abrogation of death receptor (TNFR and Fas)
signaling by either blocking TNF and Fas signaling, mimicking the death receptors,
interacting with signaling factors or mimicking death signaling factors (vFLIPS). Some
viruses have also evolved mechanisms to inhibit cellular caspases due to the expression
of viral inhibitors of apoptosis proteins (vIAP) or they express viral homologues of the
antiapoptotic protein Bcl-2. In addition, some viruses can inhibit the transcriptional
activity of p53 (reviewed in Roulston et al., 1999).
2.3.3 Apoptosis as an anti-oncogenic defense mechanism
Cancer cells, products of deregulated proliferation, have to develop mechanisms
to evade programmed cell death as well, or else be eliminated. It was shown previously
that the predisposition of cells to apoptosis by oncogenes and transformation are linked.
The regions of the HPV-16 E7 oncoprotein required for transformation (Barbosa et al.,
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1990; Edmonds and Vousden, 1989; Phelps et al., 1992) overlap with those required for
sensitizing E7 expressing cells to apoptosis upon suboptimal growth conditions (Jones et
al., 1997b). In contrast to some rodent cell lines, primary human cells are not transformed
by expression of a E7 alone. Normal human cells expressing the HPV-16 E7 oncogene
are predisposed to apoptosis (Jones et al., 1997b), and similar observations were made
with cells expressing the c-myc oncogene (Evan et al., 1992).
Cells expressing the c-myc oncoprotein have been used extensively to investigate
the relationship between apoptosis and proliferation in cells depending on the quality of
their growth conditions. It was shown that in addition to its well-documented growth-
promoting activity, myc is a powerful inducer of apoptosis, especially under conditions of
stress, genotoxic damage or depletion of survival factors (Askew et al., 1991; Evan et al.,
1992). Myc induced apoptosis upon growth factor deprivation was shown to be
independent of p53 by using a carboxyl terminal fragment of p53 that acts as a dominant
negative mutant (Juin et al., 1999). This indicates that p53 which is involved in most
apoptotic responses upon DNA damage, also called the “damage sentinel”, is not
involved in the “trophic sentinel” response of c-myc expressing cells upon deprivation of
growth factors. The apoptotic potential of c-myc appears to counteract its oncogenic
capacity (Evan and Littlewood, 1993; Evan et al., 1992; Harrington et al., 1994b). In
addition, there is a clear parallel between the activation of cell cycle progression by the
adenoviral oncoprotein E1A and the early products of other small DNA tumor viruses
and the sensitization of cells to apoptosis by activated oncogenes as well. In the absence
of well-coordinated growth signals, these viral oncogene-expressing cells are primed to
undergo apoptosis unless this response is blocked by cellular survival factors such as Bcl-
2 or by viral factors that inactivate p53 such as Ad E1B or HPV E6. A similar duality has
been described for many known growth-promoting proteins, including E2F-1 (Almasan
et al., 1995; Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994).
2.3.4 The HPV E7 oncoprotein and apoptosis
Expression of HPV-16 E7 targeted to lens or retinal photoreceptor cells induces
apoptosis in differentiating cells of transgenic mice (Howes et al., 1994; Pan and Griep,
1994). Coexpression of HPV-16 E6, which targets p53 for degradation abrogates
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apoptosis, resulting in tumorigenic progression (Pan and Griep, 1994). In this model,
cells expressing an E7 mutant that is unable to bind pRB do not undergo apoptosis. By
employing this model in mice with a p53 null background it became clear that the
observed HPV-16 E7 mediated apoptosis in the lens is mediated through p53-dependent
and p53-independent pathways (Pan and Griep, 1995). The fact that a pRB binding
deficient E7 mutant does not induce apoptosis, supported the model that E2F-1, which is
regulated by pRB may be involved in E7 mediated apoptosis. The investigation of the
lens phenotype in mice that express E7 in an E2F-null background indicated that the
ability of HPV-16 E7 to induce apoptosis is indeed partially dependent on E2F-1
(McCaffrey et al., 1999).
There is conflicting evidence on whether HPV-16 E7 can predispose cells to
apoptosis upon different stimuli in different cell systems. The p53 tumor suppressor
functions as a “damage sentinel” in a DNA damage-induced cellular apoptosis response.
HPV-16 E7 infected human foreskin keratinocytes (HFKs) are not more prone to p53-
dependent apoptosis upon DNA damage induced by cisplatin, etoposide or mitomycin C
(Liu et al., 2000), whereas these cells are sensitized to apoptosis upon treatment with
TNF- a , TNF-related apoptosis-inducing ligand (TRAIL) or sulfur mustard (Basile et al.,
2001; Stoppler et al., 1998). In contrast, expression of HPV-16 E7 inhibits the induction
of TNF- a  mediated apoptosis in normal human diploid fibroblasts (IMR90) (Thompson
et al., 2001). The expression of HPV-16 E7 in human uroepithelial cells predisposed
these cells to apoptosis in response to g -irradiation (Puthenveettil et al., 1996).
The “trophic sentinel” is engaged in response to growth factor withdrawal and is
dependent on cellular survival factors such as the Akt kinase. Its dependence on p53 is
less well established. However, it has been shown that HPV-16 E7 can predispose human
diploid lung fibroblasts to undergo apoptosis in response to growth factor deprivation
(Jones et al., 1997b). The finding that pRB remains hyperphosphorylated in HPV-16 E7
expressing cells upon growth factor withdrawal indicated that the ability of HPV-16 E7
to predispose cells to apoptosis is linked to its growth promoting activity, which triggers
the apoptosis pathway in the absence of growth factors (Jones et al., 1997b). Since HPV-
16 E7 mediated apoptosis upon growth factor deprivation can be abrogated by the
Introduction                                                                                                                                                           21
coexpression of HPV-16 E6, it has been suggested that this cell death may be dependent
on p53 (Jones et al., 1997b).
2.4 Aims of the research
HPV-16 E7 expressing cells were reported to have higher steady state levels of
p53, which is due to a prolonged half-life of the protein (Jones and Münger, 1997; Jones
et al., 1997b). The fact that HPV-16 E7 expressing cells proliferate rapidly in the
presence of high p53 levels indicates that the stabilized p53 might not be fully active as a
transcription factor. HPV-16 E7 expressing cells are predisposed to apoptosis upon
suboptimal growth conditions (Jones et al., 1997b). The finding that HPV-16 E7
mediated apoptosis is inhibited by the coexpression of HPV-16 E6, suggested that HPV-
16 E7 triggered apoptosis in primary human cells may be at least in part p53 dependent.
Hence we studied the biochemical mechanisms and molecular consequences of
HPV-16 E7 induced p53 stabilization. Moreover we determined whether the apoptotic
response of HPV-16 E7 expressing cells to growth factor deprivation was p53 dependent
and mediated by increased expression of known p53 responsive proapoptotic genes.
2.4.1 Aim 1: To investigate the biochemical mechanisms and biological
consequences of p53 stabilization by the HPV-16 E7 oncoprotein in
proliferating cells
As one part of the thesis the mechanisms of p53 stabilization and the
consequences for the proliferating HPV-16 E7 expressing cells were studied. It was
investigated whether p53 stabilization is due to an inability of mdm2 to bind to and
degrade p53 in the presence of HPV-16 E7. Other mechanisms that might be involved in
p53 stabilization by HPV-16 E7 including the possible interference of HPV-16 E7 with
the nuclear export of p53 or the folding of p53 into a degradation resistant mutant
conformation were investigated as well. Discovering the mechanism of E7 mediated
stabilization may yield new insights into how viral oncoproteins inactivate cellular
regulators to escape growth arrest or apoptosis.
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2.4.2 Aim 2: To determine the molecular components of the “tropic sentinel”
response of HPV-16 E7 expressing cells upon growth factor deprivation
To determine the mechanisms involved in HPV-16 E7 mediated apoptosis upon
growth factor withdrawal, the transcriptional involvement of p53 in the “trophic sentinel”
response in E7 expressing cells was investigated. To identify other mediators of HPV-16
E7 mediated apoptosis, gene expression profiling was performed and two genes were
observed to be upregulated more than 2 fold in HPV-16 E7 expressing cells and their
levels increased even further in these cells upon deprivation of growth factors. The two
genes are insulin-like growth factor binding proteins (IGFBPs) 2 and 5, which are
involved in regulating the availability and binding capacity of the survival factor Insulin-
like growth factor I (IGF-I) to its receptor and thereby have a major impact on the pro- or
anti-proliferative signals the cell receives. The possible roles of these two genes in HPV-
16 E7 mediated apoptosis upon growth factor deprivation was investigated. Different
apoptosis pathways were described previously and the possible involvement of these
pathways in HPV-16 E7 mediated apoptosis like the involvement of the caspase cascade,
the mitochondria and the apoptosis-inducing factor (AIF) was investigated as well.
A better understanding of the mechanisms of HPV-16 E7 mediated stabilization
and inactivation of p53 as well as HPV-16 E7 mediated apoptosis upon growth factor
withdrawal may lead to the possible development of novel treatments of HPV-associated
cervical cancer. One possible treatment could eliminate HPV-positive cervical cancer
cells by inactivating the HPV-16 E6 oncoprotein and subsequently induce HPV-16 E7
mediated apoptosis by suboptimal growth conditions.
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3. Materials and Methods
3.1 Cell culture methods
3.1.1 Cell culture and cell lines
Low passage normal human diploid lung fibroblasts (IMR90), the human
keratinocyte cell line HaCaT, the HPV negative cervical cancer cell line C33A, the breast
cancer cell lines SK-Br-3 and MCF-7, the osteosarcoma cell line U2OS and the african
green monkey kidney cells COS-7 were maintained in Dulbecco’s modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin
and 50 µg/ml streptomycin.
IMR90 cells immortalized by telomerase (hTERT) (pBABE vector with
puromycin resistance) expressing IMR90 cells that co-express p53DD (CTF), HPV-16
E6, HPV-16 E7, HPV-16 E6 and HPV-16 E7 or the empty LXSN vector (LXSN vector
with G418 resistance) were obtained from Sheila Steward (Weinberg laboratory,
Whitehead Institute, MIT, Boston). These cells were infected with either empty pBABE
or pBABE-E7 expressing retroviruses (pBABE vector with hygromycin resistance) to
obtain the following stable hTERT expressing IMR90 cell lines: hT LX, hT E7, hT E6,
hT p53DD, hT E6E7, and hT p53DDE7.
3.1.2 Retroviral infections
Recombinant retroviruses LXSN and LXSN-HPV-16 E7 were obtained from D.
Galloway and used for retroviral transduction of IMR90 cells. Recombinant retroviruses
pBABE and pBABE-HPV-16 E7 were obtained by transiently transfecting the retroviral
packaging line 293T cells (Yang et al., 1998) using the Calcium phosphate method. In
brief, 293T cells were transfected with 6 µg of pMD.MLV gagpol (helper plasmid), 2 µg
of pMD.G (VSVG pseudotype) and 8 µg of plasmid of interest. After 16 hours of
incubation cells were washed twice, new medium was added and the virus containing
supernatant was collected 48-72 hours post-transfection.
For the retroviral infection, the cells were incubated for 4 h with virus-containing
supernatant in the presence of 4 µg/ml hexadimethrine bromide (polybrene) (Sigma).
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Pooled stable cell populations were obtained by selection with 300 µg/ml G418 (Gemini
Bio-Products) for 4 days or with 150 µg/ml hygromycin.
3.1.3 Transfections
Transient transfections of IMR90 cell populations were performed by incubating
the cells in 6-well plates for 4 h at 37° C in 1 ml Opti MEM I (Gibco) containing 4 µg
DNA and 10 µg/ml polybrene followed by incubation with 24 % DMSO (ICN
Biomedicals Inc.) in Opti MEM I for 4 minutes at room temperature. The cells were
washed three times with PBS, then supplemented with DMEM with 10 % FBS, and
processed 24 hours post-transfection.
Transient transfection of U2OS cells was performed using lipofectamine
according to the manufacturer’s instructions.
3.1.4 Treatments
Geldanamycin (Sigma) was dissolved in DMSO at a concentration of 1.5 mM.
IMR90 control and E7 expressing cells and SK-Br-3 cells were treated for 4 h with 1.5
µM geldanamycin or mock treated with an equal volume of DMSO. Leptomycin B
(Sigma) was dissolved in ethanol at a concentration of 10 µg/ml. IMR90 control and E7
expressing cells were treated for 8 h with 40 ng/ml leptomycin B. Lactacystin (BIOMOL)
was dissolved in water at a concentration of 40 mM. IMR90 control and E7 expressing
cells were treated for 4 h with 40 µM lactacystin. Actinomycin D (Sigma) was dissolved
in Ethanol at a concentration of 2.5 µM. IMR90 control and E7 expressing cells were
treated for 24 h with 2.5 nM actinomycin D. Cisplatin (Sigma) was made up fresh before
each use in DMSO at a concentration of 1 mg/ml and used at the indicated
concentrations. TNF-a  (R&D Systems) was dissolved in PBS + 0.2 % BSA to a stock
concentration of 10 ng/ml and was used at the indicated concentrations. Cycloheximide
(CHX) was dissolved in H2O at a concentration of 3 mg/ml and was used at a
concentration of 30 µg/ml. UV treatment was performed by exposing cells to 50 mJ/m2 in
a stratalinker (Stratagene) followed by incubation of 3 h in DMEM + 10 % FBS. Taxol
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(paclitaxel) (Sigma) was dissolved in DMSO at a concentration of 50 mg/ml and was
used at 100 nM for 24 h followed by an incubation with serum-free medium for 48 h.
3.2 DNA and RNA analysis methods
3.2.1 RNA isolation
Total RNA was isolated using the RNeasy kit (Qiagen) according to the
manufacturers recommendations, followed by treatment with 1 U/µl DNase-I (Roche) for
1 h at 37 °C. To test for DNA contamination, RNA samples were subjected to PCR
analysis using GAPDH primers. mRNA was isolated from total RNA by using the
OligoTex kit (Qiagen) according to the manufacturer’s manual.
3.2.2 cDNA arrays
mRNA was used as a template to prepare a 32P-labeled single stranded cDNA
hybridization probe according to the manufacturers manual (Clontech) to use as a probe
on ATLAS cDNA arrays. A Human Apoptosis ATLAS cDNA array (Clontech) was
used. The signals were visualized with a STORM PhosphoImager and the results were
quantitated using ATLAS image 1.5 software (Clontech).
3.2.3 Northern blotting
For Northern Blot analyses 10 µg total RNA was separated on a 1%
formaldehyde/agarose gel, transferred to a NYTRAN SuPerCharge nylon membrane
(Schleicher & Schuell) and crosslinked with a Stratalinker (Stratagene). The cDNA
probes were 32P-labeled using the STRIP-EZ DNA kit (Ambion) following the
manufacturer’s instructions and hybridized in ExpressHyb (Clontech) according to the
manufacturer’s manual. The signals were visualized with a STORM PhosphoImager and
quantitated using ImageQuant software.
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3.3 Protein analysis methods
3.3.1 Immunoblot analyses
Cells were lysed in 1% NP-40 buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5,
1% Nonidet P-40, 0.01% PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin), immediately
scraped off the plates, incubated on ice for 20 minutes and centrifuged for 10 minutes at
4° C at 16,000 x g in a microcentrifuge. Protein concentrations of the lysates were
determined by the Bradford method (Bio-Rad). Samples containing 100 µg of protein
were separated by SDS-PAGE and transferred to a PVDF membrane (Immobilion P,
Millipore). Antibody complexes were detected by enhanced chemiluminescence
(Renaissance Enhanced Luminol Reagent, NEN Life Science Products). Primary
antibodies were used at the following dilutions: p53 (Ab-6, mouse monoclonal, 1:1000,
Calbiochem), p21CIP1/waf1 (Ab-1, mouse monoclonal, 1:1000, Calbiochem), bax (mouse
monoclonal, 1:500, Pharmingen), ß-actin (mouse monoclonal, 1:10,000, CHEMICON),
GAPDH (mouse monoclonal, 1:600, CHEMICON), E7 (mixture of 8C9, 1:100, Zymed
and ED17, 1:1000, Santa Cruz, both mouse monoclonal), mdm2 (N-20, rabbit polyclonal,
1:300, Santa Cruz), DR5 (1:500, rabbit polyclonal, IMGENEX, San Diego, CA, USA),
Ik B a  (1:200, rabbit polyclonal, Santa Cruz), cytochrome c (1:250, mouse monoclonal,
Pharmingen), apoptosis inducing factor (AIF) (1:500, rabbit polyclonal, Alexis),
cytochrome c oxidase subunit II (CoxII) (1:300, mouse monoclonal, Molecular Probes),
IGFBP-1 (C-19, 1:100, goat polyclonal, Santa Cruz), IGFBP-2 (C-18, 1:100, goat
polyclonal, Santa Cruz), IGFBP-3 (C-19, 1:100, goat polyclonal, Santa Cruz), IGFBP-4
(C-20, 1:100, goat polyclonal, Santa Cruz), IGFBP-5 (C-18, 1:100, goat polyclonal, Santa
Cruz), IGFBP-6 (C-20, 1:100, goat polyclonal, Santa Cruz). The phospho-specific p53
antibodies used were Ser6, Ser9, Ser20, Ser37, Ser392 (1:1000, rabbit polyclonal, Cell
Signaling Technology), Ser15 (1:2000, mouse monoclonal, Cell Signaling Technology)
and Ser46 (1:1000, rabbit polyclonal, gracious gift from Y. Taya, Tokyo, Japan).
Secondary HRP-conjugated antibodies were used at 1:10,000 dilutions (mouse, rabbit:
Amersham, goat: Santa Cruz). ECL images were acquired using a Fluoro-S MultiImage
MAX (Bio-Rad) with a supercooled digital camera (Nikon) and quantitated using
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QuantityOne software (Bio-Rad). Equal loading was controlled using GAPDH or ß-actin
immunoblots.
3.3.2 Immunoprecipitations
Cells were lysed and processed as described previously. Samples containing 0.5-1
mg total protein were incubated for 1.5 h at 4° C with 2 µg of specific antibody, followed
by protein A-sepharose beads (Pharmacia) or protein G PLUS-agarose beads (Santa
Cruz) for 1 h at 4° C at constant rotation. The p53 antibodies used were PAb1620
(Calbiochem) and PAb240 (Calbiochem), and for mdm2 Ab-1 (Calbiochem) was used.
Immuncomplexes were washed 4 to 6 times in 1% NP 40 lysis buffer and subjected to
SDS-PAGE and immunoblot analysis. An anti-mouse k  light chain specific secondary
antibody (1:10,000, Southern Biotechnology Associates) was used to facilitate detection
of immunoprecipitated p53.
3.3.3 Half life determinations
Control and E7 expressing IMR90 cells were treated with 30 µg/ml of the
translation inhibitor cycloheximide (Sigma) for the indicated time periods. The cells were
lysed and processed as described previously and the p53 steady state levels were
determined by immunoblot analysis. Images were digitally acquired using a BioRad
Fluor-S-Max Multi-imager and quantitated using the manufacturer’s software. The levels
of p53 were normalized for ß-actin expression.
3.3.4 Immunofluorescence analyses
Cells were transiently transfected as described above. After 36 h the cells were
fixed in 2% paraformaldehyde for 30 min at 25°C, washed in PBS, permeabilized with
100% Methanol for 10 min at -20°C and washed with PBS. For the detection of AIF and
Tid in untransfected IMR90 cells the cells were permeabilized in 4% paraformaldehyse
with 0.2 % Triton X for 20 minutes at room temperature. After that the cells were
incubated with 2.5% goat serum in PBS for 30 min at 37°C, washed with PBS, incubated
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with primary antibody (p53, mouse monoclonal, Ab-6, Calbiochem, 1:100; AIF, rabbit
polyclonal, Santa Cruz 1:25; Tid, mouse monoclonal, hybridoma cell supernatant, 1:5)
for 1.5 h at 37°C, washed twice in PBS followed by an incubation with the FITC-coupled
secondary goat a- mouse antibody (1:200) for p53, Cy3-coupled secondary
goat a- mouse antibody (1:500) for Tid and Alexa Flour-coupled goat a- rabbit antibody
(1:400) for AIF for 1 h at 37°C. The nuclei were stained with Hoechst 33258 (1:2000 in
H2O).
3.3.5 Luciferase assays
Cells were transfected in 6-well-plates with 500 ng of firefly luciferase reporter
plasmid either under the control of an artificial p53 responsive promoter carrying 17
tandem repeats of the p53 consensus DNA binding sequence derived from the ribosomal
gene cluster (Kern et al., 1991) (pRGC-luc) or under the control of the p53 responsive
human mdm2 promoter (pGL2-mdm2-luc) (Zauberman et al., 1995) (kind gifts from M.
Oren). 20 ng of the non-inducible renilla luciferase reporter plasmid (pRL-TK) was
cotransfected as a transfection control. The cells were lysed after 24 hours in 30 µl lysis
buffer (Dual-Luciferase Reporter Kit, Promega) per well, scraped off the plate and
centrifuged for 10 min at 4° C at 16,000 x g. The supernatants were subjected to the dual
luciferase assay and the firefly luciferase activity was normalized for renilla luciferase
expression.
3.3.6 Subcellular fractionation
Stable control and E7 expressing IMR90 cells were washed in PBS and scraped in
sucrose buffer (250 mM sucrose, 10 mM MOPS pH 7.2, 1 mM EDTA, 0.01% PMSF, 1
µg/ml aprotinin, 1 µg/ml leupeptin). The cells were then homogenized by 30 strokes of a
Teflon tissue homogenizer (Glas-Col, Terre Haute, IN). Nuclei were pelleted at 700 x g
at 4 ° C for 10 min. The supernatant was centrifuged at 10,000 x g at 4° C for 10 min to
pellet the mitochondria. The supernatant represents the cytoplasmic fraction. The nuclear
pellet was resuspended in 1% NP 40 buffer and the nuclear lysate was cleared by
centrifugation for 10 min at 4 ° C at 16,000 x g. The mitochondrial pellet was lysed in cell
lysis buffer provided with the Quantikine human cytochrome c ELISA kit (R&D
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systems) and cleared by centrifugation for 10 min at 4° C at 16,000 x g. Equal amounts of
protein from the cytoplasmic and nuclear fraction were separated by SDS-PAGE and p53
levels were determined by immunoblotting. To determine cytochrome c release equal
amounts of protein of the cytoplasmic and the mitochondrial fraction were used in the
Quantikine human cytochrome c ELISA kit.
3.3.7 Two-dimensional gel electrophoresis
For two dimensional (2D) gel analyses of endogenous p53 (Stewart et al., 2001),
1 mg of protein lysate from LXSN cells or 250 µg of protein lysate from E7 cells were
prepared in a final volume of 600 µl of isoelectric focusing (IEF) sample buffer (9.5 M
urea (Pharmacia), 2% NP-40, 2% ß-mercaptoethanol, 0.2% ampholytes pH 5-8
(Pharmacia), 0.001% bromophenol blue).  A truncated form of recombinant human p53
(amino acids 1-353) was incubated in each sample as an internal standard to permit
alignment of p53 phospho-forms; the truncated human p53 was prepared as previously
described (Szak and Pietenpol, 1999). IEF was performed using the PROTEAN IEF
system (BioRad) and 17 cm isoelectric strip gels pH 5-8 (BioRad). The isoelectric gels
were passively rehydrated for 10 h in IEF sample buffer containing the protein lysate
prior to focusing for 60,000 volt-hours. After IEF, gels were incubated for 15 min in
equilibration buffer I (6 M urea, 2% SDS, 0.375 M Tris (pH 8.8), 20% glycerol, 130 mM
DTT) and 15 min in equilibration buffer II [6 M urea, 2% SDS, 0.375 M Tris (pH 8.8),
20% glycerol, 135 mM iodoacetamide (Sigma)] prior to separation by SDS-PAGE.
Detection of p53 was by immunoblot using PAb1801 (1 µg/ml; Calbiochem).
3.3.8 Electrophoretic Mobility Shift Assay (EMSA) for NF B
The doublestranded H2K oligonucleotide with BamH1 overhangs (sense 5’-
GATCCAGGGCTGGGGATTCCCCATCTCCACAGG-3’; antisense 5’-GATCCCTGT
GGAGATGGGGAATCCCCAGCCCTG-3’) was radioactively labeled in a 25 µl
reaction using 3.5 µl 32P a -dATP (6000 µCI/µl), 250 ng H2K oligonucleotide, 2.5 µl 10x
Klenow buffer, 1 µl Klenow and 1.8 µl 5 mM dNTP mix without dATP. The mixture was
incubated at 30°C for 30 minutes followed by a purification using the QIAquick
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Nucleotide Removal kit (Qiagen). The efficiency of the labeling was determined by
scintillation counter.
Cells were washed in PBS and lysed in EBL buffer (20 mM HEPES/NaOH, pH
7.9, 350 mM NaCl, 20 % glycerin, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 1 %
NP-40, 0.1 mM NaO3VO4, 1 mM DTT, 0.57 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml
aprotinin, 1 mM NaF, 10 mM b -glycerophosphate) for 30 minutes at 4˚C. Lysates were
cleared at 14,000 rpm for 10 minutes at 4˚C and the DNA binding assay was performed
as follows: 5 µg of protein lysate was incubated with 20,000 cpm labeled H2K
oligonucleotide in DNA binding buffer (40 mM HEPES/NaOH, pH 7.9, 120 mM KCl, 8
% Ficoll, 0.5 mM DTT, 0.1 mg/ml BSA, 0.1 µg/µl poly dIdC, 0.1 % NP40) in a total
reaction volume of 20 µl for 30 minutes at 30°C. Supershifts were performed by
preincubating the protein lysate with a -p50 (Rockland) or a -p65 antibodies (Santa Cruz)
for 10 minutes on ice. Protein lysates form U2OS cell transfected with p50 and p65
expression plasmids (gracious gifts of M. Hinz, MDC Berlin, Germany) were used as
positive controls. The complexes were separated on a 4 % acrylamide gel and the
vacuum-dried gel was exposed to X-ray film.
3.3.9 Electrophoretic Mobility Shift Assay (EMSA) for p53
The oligonucleotide provided in the p53 NUSHIFT kit (GENEKA) was
radioactively labeled according to the manufacturer’s instructions. The efficiency of the
labeling was determined by scintillation counter.
Cells were washed in PBS and lysed in p53 EMSA lysis buffer (100 mM Tris-Cl
pH 8.0, 100 mM NaCl, 1 % NP-40, 1 mM EDTA, 0.57 mM PMSF, 1 µg/ml leupeptin, 1
µg/ml aprotinin) for 30 minutes at 4˚C. Lysates were cleared at 14,000 rpm for 5 minutes
at 4˚C and the DNA binding assay was performed using the p53 NUSHIFT kit
(GENEKA) according to the manufacturers’ instructions. 20 µg of protein lysate was
used per reaction. The complexes were separated on a 4% acrylamide gel and the
vacuum-dried gel was exposed to X-ray film.
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3.4 Apoptosis analysis methods
3.4.1 Caspase Activity Assay
Caspase activity assays were carried out according to manufacturers instructions
(Clontech, ApoAlert Caspase 3 and 8 Fluorometric Assay Kit). 1x106 cells from different
stable IMR90 cell lines that were subject to different treatments were lysed and incubated
with caspase 3 or caspase 8 specific substrates for 1 hour at 37°C. The addition of
caspase specific inhibitors served as a control to assure the measurement of specific
caspase activity. The resulting enzymatic activity was determined by measuring the
emitted fluorescence of the caspase cleaved substrate in a fluorometer.
3.4.2 Hoechst Staining
Cells treated to induce apoptosis by different stimuli and their control treated
counterparts were fixed with 100 % methanol vapors for 10 minutes and stained with 1
m g/ml of bisbenzimide (Sigma, Hoechst 33258) in dH2O for 8 minutes. Apoptotic nuclei
were visualized by fluorescence microscopy as described previously (Jones et al., 1997b).
Cells were scored as apoptotic based upon the condensed nuclear morphology and
expressed as a percentage of total cells.
3.4.3 DNA fragmentation assay
DNA fragmentation was measured by using the Cell Death Detection ELISA plus
system (Roche) according to the manufacturers manual. 1x104 cells were used for each
assay and experiments were performed in triplicate.
3.4.4 Cytochrome c release assay
Cells treated to induce apoptosis by different stimuli and their control treated
counterparts were subjected to subcellular fragmentation. 2µg of the cytoplasmic and
mitochondrial fraction were used to determine the cytochrome c content using the
Quantikine human cytochrome c ELISA assay (R&D systems) according to the
manufacturers manual.
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4. Results
4.1 Stabilization and functional impairment of the tumor suppressor
p53 by the human papillomavirus type 16 E7 oncoprotein
4.1.1 The functional impairment of the tumor suppressor p53 by the HPV-16 E7
oncoprotein
4.1.1.1 The stabilized p53 in HPV-16 E7 expressing cells is transcriptionally
incompetent.
It was reported previously that overexpression of the HPV-16 E7 oncogene results
in accumulation (Demers et al., 1996) and increased half-life of the p53 protein (Jones
and Münger, 1997; Jones et al., 1997b). These results are surprising as increased p53
activity is associated with cell cycle arrest or apoptosis. However, HPV-16 E7 expressing
cells grow rapidly. Therefore it was critical to analyze p53 activity in proliferating HPV-
16 E7 expressing cells.
Figure 8:  Estimation of p53 half-life. Cultures were treated with cycloheximide (CHX) for the indicated
periods of time and 100 µg aliquots of protein lysates analyzed by SDS-PAGE and immunoblotting.
Quantification was performed after normalization for ß-actin expression and is shown underneath.
We generated stable cell lines by infecting IMR90 human diploid lung fibroblasts
with empty retroviral vector LXSN (LX) or LXSN vector expressing HPV-16 E7 (E7). In
agreement with previous studies (Jones and Münger, 1997) the p53 steady state levels
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were consistently 3 to 4 times higher in HPV-16 E7 expressing IMR90 cells compared to
control cells and the half-life of p53 was extended in stable HPV-16 E7 expressing cells
(Fig. 8). Previous studies showed that p53 mRNA levels are not increased in HPV-16 E7
expressing cells indicating that the increased levels of p53 protein are mostly due to
increased protein stability (Jones et al., 1997b). Note that the decrease of p53 levels in
both control (LX) and HPV-16 E7 expressing cells is greater between the 0 and 1 hour
time points than at subsequent times suggesting that these cells may contain two p53
populations with different half lives.
There is conflicting evidence concerning the transcriptional activity of the
stabilized p53 in HPV-16 E7 expressing cells. A previous study demonstrated that
transcription of p21CIP1, a major transcriptional target of p53, was not significantly altered
in HPV-16 E7 expressing cells (Jones et al., 1999). Consistent with this finding it was
also reported that HPV-16 E7 can dampen expression of p53-responsive reporter
plasmids in transient assays (Massimi and Banks, 1997). In contrast, another study
showed that stable HPV-16 E7 expressing fibroblasts contained elevated mdm2 mRNA
levels derived from the p53-responsive P2 promoter (Seavey et al., 1999) suggesting that
p53 may be transcriptionally active in HPV-16 E7 expressing cells. To determine
whether the elevated p53 levels correlate with an increase in transcriptional activity of
p53, transient reporter assays were performed. Control and HPV-16 E7 expressing
IMR90 cells were transfected with a constant amount of firefly luciferase reporter
plasmid under the control of an artificial p53-responsive promoter consisting of 17 p53
binding sites (pRGC-luc). Activity was determined and normalized against the expression
of the non-p53-responsive renilla luciferase reporter pRL-TK that was cotransfected.
Expression of the p53 responsive reporter construct was decreased in HPV-16 E7
expressing cells to a level of approximately 40% of control cells (Fig. 9A) even though
this HPV-16 E7 expressing cell population contains 3.6 fold higher p53 levels than
control cells (Fig. 10). Activity of the renilla luciferase reporter was not affected by HPV-
16 E7 expression (data not shown).
Next the expression levels of known p53 target genes in control and HPV-16 E7
expressing IMR90 cells was investigated performing expression profiling using a cDNA
array. The array contained a total of 12 known p53 responsive genes. The basal level of
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expression of the p53 responsive genes was variable, but none of these genes was
expressed at a significantly higher level in HPV-16 E7 expressing cells (Fig. 9B). As
expected from earlier studies (Cheng et al., 1995), expression of PCNA, a marker of
proliferation, was higher in E7 expressing cells than in control cells (Fig. 9B).
Figure 9:  Decreased transcriptional activity of the stabilized p53 in E7-expressing IMR90 cells. (A) Cells
were transfected with the artificial p53-responsive firefly luciferase reporter plasmid pRGC-luc. Activity
values were normalized for expression of a non-responsive renilla luciferase reporter. Values represent
averages and standard deviations of an experiment performed in triplicate. (B) Expression analysis of a set
of p53 responsive genes by transcriptional profiling. A “Human Apoptosis ATLAS” cDNA nylon array
(Clontech) was analyzed by sequential hybridization with 32P-labeled single stranded cDNA probes. PCNA
is a known E7-responsive gene and was used as a positive control.
The protein levels of some p53 target genes on the cDNA array were determined
by immunoblot analysis as well (Fig. 10). Steady state levels of the pro-apoptotic p53
target genes bax (Miyashita and Reed, 1995) and DR5 (alias TRAIL-R2/Apo2/Killer)
(Wu et al., 1997) were only slightly increased or were unchanged, respectively (Fig. 10).
Increased levels of p21CIP1 have been observed in HPV-16 E7 expressing cells and are a
consequence of increased protein stability (Jones et al., 1997b) and there is no
comparable increase in mRNA levels (Fig. 9B).
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Figure 10:  Immunoblot analysis of p53, and the p53 transcriptional targets p21CIP1 (p21), bax and DR5
(alias TRAIL-R2/Apo2/Killer). Expression of HPV-16 E7 is also shown. Relative expression levels of each
protein were determined after correction for GAPDH and is indicated underneath the panels in arbitrary
units.
4.1.1.2 Exogenous p53 is transcriptionally active in HPV-16 E7 expressing cells.
To investigate whether HPV-16 E7 can interfere with the transcriptional activity
of exogenous p53 we transiently transfected control and HPV-16 E7 expressing IMR90
Figure 11:  Transcriptional activity of exogenous p53 in control (LX) and HPV-16 E7-expressing (E7)
IMR90 populations.  Cells were cotransfected with 500 ng of the p53-responsive firefly luciferase reporter
pRGC-luc and the indicated amounts of p53.  Activity values were normalized for expression of a non-
responsive renilla luciferase reporter. Values represent averages and standard deviations of an experiment
performed in triplicate.
LX E7
1 3.6
p53
p21
1 1.9
bax
1 1.4
DR5
1 1
E7
GAPDH
p53 (µg)
0 0.001 0.005 0.01 0.05 1
LX
E7
100
200
150
50
0L
u
ci
fe
ra
se
 a
ct
iv
it
y
 (
R
LU
)
Results                                                                                                                                                                   36
cells with increasing amounts of p53 and the p53-responsive luciferase reporter plasmid
pRGC-luc and determined its transcriptional activity by luciferase assays. In agreement
with our previous result (Fig. 9A) transcriptional activity of endogenous p53 is
diminished by approximately 60% in HPV-16 E7 expressing cells compared to the
control population. Exogenous p53, however, was able to efficiently activate reporter
gene expression in HPV-16 E7 expressing cells to a similar level as in control cells (Fig.
11). This indicates that in IMR90 cells, HPV-16 E7 does not impair the transcriptional
activity of exogenous p53.
4.1.2 The susceptibility of p53 to mdm2 mediated degradation in HPV-16 E7
expressing cells
4.1.2.1 p53 is bound to mdm2 in HPV-16 E7 expressing cells.
The major regulator of p53 stability in cells is mdm2, which is a transcriptional
target of p53 as well. Mdm2 binds to p53 and marks it for degradation. Upon cellular
stress, such as DNA damage, p53 becomes modified and is no longer susceptible to
mdm2 binding. This increase in p53 activity results in elevated mdm2 levels and this
feedback loop response terminates the p53 response. Due to the importance of mdm2 for
the regulation of p53 activity it was critical to determine mdm2 activity in HPV-16 E7
expressing cells containing stabilized p53.
It has been reported previously that HPV-16 E7 expressing cells contain higher
mdm2 levels (Seavey et al., 1999; Thomas and Laimins, 1998). In our cells steady state
levels of mdm2 mRNA and protein in control and HPV-16 E7 expressing cells were too
low to detect by transcriptional profiling (Fig. 9B) or direct immunoblot analysis (data
not shown), respectively. Hence, we performed coupled
immunoprecipitation/immunoblot analyses and found that mdm2 levels were increased
approximately 1.8 fold in HPV-16 E7 expressing cells compared to control cells (Fig.
12A, upper panel). This is a less dramatic increase than previously reported in other cell
systems (Seavey et al., 1999; Thomas and Laimins, 1998). Since a previous study
reported that HPV-16 E7 could interfere with the interaction of mdm2 and p53 (Seavey et
al., 1999), the amount of p53 bound to mdm2 was determined by coimmunoprecipitation
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experiments. Approximately 2.5 fold more p53 was coimmunoprecipitated with mdm2 in
HPV-16 E7 expressing cells, which parallels the increase of mdm2 (1.8 fold) in these
cells (Fig. 12A). These results suggest that mdm2 is effectively bound to p53 in HPV-16
E7 expressing IMR90 cells indicating that HPV-16 E7 does not interfere with the
association of p53 and mdm2.
Figure 12:  Expression of mdm2 and the mdm2 homologue mdmX in control (LX) and HPV-16 E7
expressing (E7) IMR90 cells. (A) p53 is in complex with mdm2 in E7-expressing cells. Equal amounts of
protein lysates were immunoprecipitated with mdm2 specific antibodies followed by immunoblot analysis
for mdm2 (upper panel) and co-precipitated p53 (lower panel). Quantitation of the signals is shown
underneath. (B) Activity of the p53-responsive P2 promoter of human mdm2. Cells were transfected with
the corresponding firefly luciferase reporter construct.  Activity values were normalized for expression of a
non-responsive renilla luciferase reporter. Values represent averages and standard deviations of an
experiment performed in triplicate. (C) Northern blot analysis of mdmX RNA expression. Relative levels
of mdmX mRNA are shown underneath and have been corrected for equal loading as determined by actin
mRNA.
Since the mdm2 promoter contains p53 responsive elements, it was determined
whether the transcriptional activity of the mdm2 promoter is increased in HPV-16 E7
expressing cells. A luciferase reporter assay was performed by transfecting a reporter
plasmid under the control of the p53 responsive element of the human mdm2 P2
promoter into control and HPV-16 E7 expressing IMR90 cells. Similar to the synthetic
p53 responsive reporter construct (Fig. 9A), the expression of the mdm2 reporter plasmid
was decreased in HPV-16 E7 expressing cells to a level of approximately 40% compared
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to control cells (Fig. 12B). These experiments further support the notion that HPV-16 E7
mediated p53 stabilization does not lead to a concomitant increase of transcriptional
activity.
The recently described mdm2 homologue, mdmX, was reported to bind and
stabilize p53 by protecting it from mdm2-mediated degradation (Jackson and Berberich,
2000). Interestingly, mdmX-bound p53 is transcriptionally inert (Shvarts et al., 1997).
Furthermore, mdmX can bind and stabilize mdm2 and inhibit its ability to degrade p53
(Sharp et al., 1999). Hence mdmX appeared an attractive candidate to mediate HPV-16
E7 effects on p53. Analysis of mdmX protein levels in HPV-16 E7 expressing cells has
not been conclusive due to limitations of the existing antibodies. Northern blot analyses
revealed a slight, 1.4 fold increase of mdmX mRNA in HPV-16 E7 expressing cells (Fig.
12C). Hence it is possible that mdmX may be involved in p53 stabilization in HPV-16 E7
expressing cells.
4.1.2.2 Stabilized p53 in HPV-16 E7 expressing cells is susceptible to degradation by
exogenous mdm2.
To determine whether HPV-16 E7 can protect p53 from degradation by
exogenous mdm2, mdm2 was transiently expressed in stable HPV-16 E7 expressing
IMR90 cells and changes in p53 levels were determined by immunofluorescence.
Transfection of HPV-16 E6, which induces E6AP-mediated p53 degradation, was used as
a positive control. The DS-red plasmid encodes a fluorescent protein, and was used as
transfection marker for these experiments. Like HPV-16 E6, expression of mdm2
decreased p53 levels in stable HPV-16 E7 expressing cells (Fig. 13). This indicates that
HPV-16 E7 stabilized p53 is still susceptible to degradation by exogenous mdm2.
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Figure 13:  Stabilized p53 in HPV-16 E7-expressing cells remains susceptible to degradation by
exogenous mdm2. HPV-16 E7 expressing IMR90 cells were transiently transfected with mdm2 or HPV-16
E6 as a positive control. Untransfected E7-expressing IMR90 cells (U) are shown as controls. The
autofluorescent protein DS-red was cotransfected to allow specific identification of the transfected cells.
p53 was detected by immunofluorescence. Nuclei were visualized by Hoechst staining.
4.1.3 The stabilization of the tumor suppressor p53 by the HPV-16 E7 oncoprotein
Several other factors may also contribute to p53 stability and activity. Various
forms of cellular stress result in stabilization and accumulation of the p53 protein as a
consequence of posttranslational modifications. Changes in p53 phosphorylation status
have been implicated in both stabilization and activation of the protein (reviewed in
Stewart and Pietenpol, 2001). In addition, changes in conformation, subcellular
localization or the inhibition in degradation can result in stabilization and activation of
the p53 protein (Bosari et al., 1995; Cho et al., 1994; Elmore et al., 1997; Moll et al.,
1995; Moll et al. , 1992; Pavletich et al. , 1993; Schlamp et al. , 1997; Ueda et al. , 1995;
van den Heuvel et al., 1993).
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4.1.3.1 No significant changes in the number of p53 phospho-forms in HPV-16 E7
expressing cells.
To determine if increased p53 levels in HPV-16 E7 cells were associated with
changes in p53 phosphorylation we performed two-dimensional gel electrophoresis in
collaboration with the laboratory of J. Pietenpol at Vanderbilt University in Nashville,
TN. To adjust for the different p53 levels in the two cell lines, 1 mg of protein lysate
from control cells and 250 µg protein from HPV-16 E7 expressing IMR90 cells were
analyzed (Fig. 14). A recombinant carboxyl terminal truncated human p53 protein (amino
acids 1-353) was added to the IEF sample buffer to serve as internal standard for
alignment of the indicated phospho-forms (Stewart et al., 2001). Although several
phosphorylated p53 species were detected, with the exception of the most highly
phosphorylated isoform, a significant difference in p53 phosphorylation was not observed
between the control and HPV-16 E7 expressing cells.
Figure 14:  No changes in the number if phospho-forms in the stabilized p53 in HPV-16 E7 expressing
cells. Two dimensional SDS-PAGE analysis of p53 was performed to analyze aliquots containing similar
amounts of p53 (1 mg LX; 250 µg E7). P0 denotes unphosphorylated p53.
4.1.3.2 Wild type conformation of p53 in HPV-16 E7 expressing IMR90 cells.
The tumor suppressor p53 is inactivated in many cancers by being folded in a
mutant conformation (Finlay et al., 1988; Milner and Medcalf, 1991; Milner et al., 1991;
Whitesell et al., 1997). This misfolding results in the stabilization of the inactive protein.
To investigate whether the stabilized p53 in HPV-16 E7 expressing cells is in a mutant
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conformation we performed immunoprecipitation experiments with conformation-
specific antibodies. The antibody PAb1620 preferentially recognizes wild type
conformation p53 and the antibody PAb240 preferentially detects p53 with a mutant
conformation (Gannon et al., 1990). HaCaT cells, which contain a p53 with a mutant
conformation (Lehman et al., 1993), and C33A cells, which contain a p53 with a point
mutation at codon 273 (Scheffner et al., 1991) that has a wild type conformation
(Medcalf and Milner, 1993), were used as controls. Since these are mutant forms of p53
Figure 15:  The stabilized p53 in HPV-16 E7 expressing cells is in a wild type conformation. (A)
Immunoprecipitations with p53 antibodies PAb1620 and PAb240 were performed with lysates of control
(LX) and HPV-16 E7-expressing (E7) IMR90 cells (1 mg), HaCaT and C33A (C33) cells (500 µg)
followed by p53 immunoblot analysis. PAb1620 preferentially recognizes wild type conformation p53,
whereas PAb240 preferentially precipitates mutant conformation p53.  Samples containing 100 µg total
protein were used as controls for direct Western Blots.  Background bands specific to each of the antibodies
used were detected in the “No lysate” control lanes and are indicated by a (*), immunoprecipitated p53 is
indicated by arrows  (B) Control (LX) and HPV-16 E7 expressing (E7) IMR90 were treated with
geldanamycin, a compound that disrupts complexes of mutant p53 and hsp90 and renders p53 susceptible
for proteasomal degradation. SK-Br-3 cells contain hsp90-bound mutant p53 and were used as a positive
control. Levels of p53 were determined by immunoblot analysis normalized for GAPDH levels and are
shown underneath.
they do not exactly comigrate with the wild type p53 in IMR90 cells. Precipitation with
the wild type conformation specific PAb1620 but not with mutant conformation specific
PAb240 yielded a detectable signal in HPV-16 E7 expressing cells (Fig. 15A). These
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results suggest that the majority of p53 in HPV-16 E7 expressing cells is retained in a
wild-type conformation, which correlates with p53 being able to bind to its consensus
sequence and induce transcription as well as it being in a conformation susceptible to
mdm2 binding.
To corroborate this result we next determined whether the stabilized p53 in HPV-
16 E7 expressing cells is bound to hsp90. Hsp90 can bind to p53 that is in a mutant
conformation and stabilize it by preventing proteasome-mediated degradation
(Blagosklonny et al., 1996). Geldanamycin is a drug that disrupts the interaction of
mutant conformation p53 with hsp90 and renders it susceptible for proteasomal
degradation (Blagosklonny et al., 1996; Nagata et al., 1999; Whitesell et al., 1997).
Control and HPV-16 E7 expressing cells were treated with geldanamycin and p53 steady
state levels were determined by immunoblotting. The breast cancer cell line SK-Br-3
contains hsp90-bound p53 and was used as a positive control (Whitesell et al., 1997). The
p53 levels remained unchanged in control and HPV-16 E7 expressing cells upon
Geldanamycin treatment, while the p53 level in the control cells SK-Br-3 cells decreased
(Fig. 15B). These results suggest that the stabilized p53 in HPV-16 E7 expressing cells is
not complexed to hsp90. Taken together these results indicate that the stabilized p53 in
HPV-16 E7 expressing cells is in a wild type conformation.
4.1.3.3 The stabilized p53 in HPV-16 E7 expressing cells is localized to the nucleus.
p53 signaling can be inhibited by mechanisms other than mutations or
conformational alterations. One such mechanism involves aberrant subcellular
localization. We determined whether expression of HPV-16 E7 alters the subcellular
localization of p53. Nuclear and cytoplasmic fractions were prepared from control and
HPV-16 E7 expressing cells, subjected to SDS-PAGE and p53 immunoblot analysis.
Ik B a  is an exclusively cytoplasmic protein and was used as a marker. Some p53 was
detected in the cytoplasmic fractions in both control and HPV-16 E7 expressing cells, but
the ratio between cytoplasmic and nuclear p53 was similar in both cell populations (Fig.
16). Hence, the subcellular localization of p53 is not altered in HPV-16 E7 expressing
cells.
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Figure 16:  p53 is nuclear in control (LX) and HPV-16 E7-expressing (E7) IMR90 cells. Nuclear (N) and
cytoplasmic (C) fractions were subjected to p53 immunoblot analysis. Ik B was used as a cytoplasmic
marker. The ratio of cytoplasmic to nuclear p53 (C/N ratio) is indicated.
4.1.3.4 Expression of HPV-16 E7 does not block nuclear export or proteasomal
degradation of p53 per se.
Since the stabilized p53 is mainly nuclear in HPV-16 E7 expressing cells it was
investigated whether HPV-16 E7 might block nuclear export of p53, which might result
in its stabilization. Control and HPV-16 E7 expressing IMR90 cells were treated with the
 Figure 17:  The nuclear export or proteasomal degradation of the stabilized p53 inHPV-16 E7 expressing
cells is not generally impaired. Cells were treated for 4 h with 40 µM lactacystin (LC - a proteasome
inhibitor), or for 8 h with 40 ng/ml leptomycin B (LMB - a nuclear export inhibitor) and p53 levels were
determined by immunoblot analyses. Treatment with a radiomimetic dose (2.5 nM) Actinomycin (Act D)
for 24 hours was used as a positive control. GAPDH is shown to document equal loading.
nuclear export inhibitor leptomycin B (LMB) and p53 steady state levels were
determined by immunoblotting. p53 steady state levels increased to a similar extent in
control and HPV-16 E7 expressing cells (Fig. 17). This result indicates that HPV-16 E7
expression does not block the nuclear export of p53. Since it has been reported that HPV-
16 E7 can interact with the S4 subunit of the 26S proteasome (Berezutskaya and Bagchi,
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1997) we determined whether HPV-16 E7 might stabilize p53 by generally interfering
with the proteasomal degradation machinery. Control and HPV-16 E7 expressing IMR90
cells were treated with the proteasome inhibitor lactacystin. Similar increases in p53
steady state levels were observed in control and HPV-16 E7 expressing cells, indicating
that HPV-16 E7 does not generally interfere with the proteasomal degradation machinery
(Fig. 17). Treatment with the DNA damaging agent actinomycin D, which results in p53
stabilization in both control and HPV-16 E7 expressing cells (Demers et al., 1994a;
Slebos et al., 1994), was used as a control in these experiments (Fig. 17).
4.2 The “trophic sentinel” response of HPV-16 E7 expressing cells
upon growth factor withdrawal
4.2.1 The involvement of the tumor suppressor p53 in the “tropic sentinel”
response of HPV-16 E7 expressing cells
Oncogenes promote apoptosis under several conditions. Previous studies have
shown that the expression of HPV-16 E7 predisposes cells to apoptosis upon growth
factor withdrawal (Jones et al., 1997b). It is not clear, however, whether this “trophic
sentinel” response is mediated by p53. The involvement of p53 in most other apoptotic
responses, such as upon DNA damage, is well established, but the “trophic sentinel”
response upon limitation of growth factors is not as well studied as the “damage sentinel”
response.
4.2.1.1 The stabilized p53 in HPV-16 E7 expressing cells is not phosphorylated at
known serine residues upon growth factor deprivation
Changes in the p53 phosphorylation status have been implicated in both
stabilization and activation of the protein (reviewed in Stewart and Pietenpol, 2001). To
determine whether the stabilized p53 in HPV-16 E7 expressing cells is differentially
phosphorylated upon growth factor withdrawal, the phosphorylation status of known
serine residues was probed using phosphospecific antibodies in immunoblot analyses. No
increase in phosphorylation of p53 at serine residues 6, 9, 15, 20, 37, 46 or 392 was
observed in apoptotic HPV-16 E7 expressing IMR90 cells  (Fig. 18). UV treated COS7
cells were used as positive controls for the phosphospecific antibodies (Fig. 18). These
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Figure 18:  p53 is not phosphorylated in HPV-16 E7 expressing cells upon growth factor deprivation. The
phosphorylation status of p53 in control and HPV-16 E7 expressing IMR90 cells in the presence and
absence of growth factors was determined by immunoblot analyses using antibodies specific for known
serine phosphorylation sites. UV treated COS7 cells served as positive controls for the phospho-specific
antibodies. The total amount of p53 protein in control (LX) and HPV-16 E7 (E7) expressing IMR90 cells
was determined as well. The protein expression levels of GAPDH were used as a loading control.
findings are consistent with the 2 dimensional gel electrophoresis studies that showed no
changes in the number of phospho-forms in the stabilized p53 in proliferating HPV-16 E7
expressing cells compared to control cells (Fig. 14). These data indicate that the
stabilized p53 is not activated as a transcription factor in HPV-16 E7 expressing cells by
phosphorylation upon growth factor withdrawal.
4.2.1.2 The DNA binding activity of p53 in HPV-16 E7 expressing cells is not
enhanced upon growth factor withdrawal.
P53 has to bind to its binding sequence in the promoter region of the target gene
to activate transcription (el-Deiry et al., 1992; El-Deiry et al., 1993). Since the stabilized
p53 in growth factor deprived HPV-16 E7 expressing cells is not phosphorylated at
known serine residues and is thus likely not transcriptionally active it was investigated
whether it is capable of binding to its DNA consensus sequence at all. A p53 EMSA was
performed using whole cell lysates from control (LX) and HPV-16 E7 (E7) expressing
cells grown in the presence and absence of growth factors. The EMSA showed that the
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Figure 19:  The DNA binding activity of p53 in control and HPV-16 E7 expressing IMR90 cells does not
change upon growth factor withdrawal. The DNA binding capacity of p53 in control and HPV-16 E7
expressing IMR90 cells upon growth factor deprivation was determined by electrophoretic mobility shift
assay (EMSA). Raji cell lysates served as positive control. The p53/oligonucleotide complexes (p53) and
the supershifted p53/oligonucleotide/antibody complexes (p53/Ab) are indicated, as well as a nonspecific
band (ns). Non-radioactive labeled oligonucleotides containing either wild-type (wt) or mutant (mut) p53
DNA binding consensus sequences were used for competition studies. The free probe was run off the gel to
guarantee adequate separation of the complexes.
stabilized p53 in proliferating HPV-16 E7 expressing cells can bind to its DNA
consensus sequence. Furthermore no increase in the DNA binding activity of p53 in
growth factor deprived control and HPV-16 E7 expressing IMR90 cells was observed
(Fig. 19). This indicates that the p53 in proliferating and apoptotic HPV-16 E7 expressing
cells is capable of binding to its consensus sequence at a similar efficiency. Taken
together these results indicate that p53 is not phosphorylated at known serine residues
and that its ability to bind DNA is neither impaired nor enhanced in HPV-16 E7
expressing IMR90 cells in the presence or absence of growth factors.
4.2.1.3 The stabilized p53 is not active as a transcription factor during HPV-16 E7
mediated apoptosis.
The transcription factor activity of p53 is elevated in most apoptotic settings
(Bennett, 1999; Zornig et al., 2001), and several p53 responsive genes directly contribute
to the apoptotic response. Since it was shown previously that the stabilized p53 in HPV-
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16 E7 expressing cells can be activated as a transcription factor upon DNA damage, it
was critical to investigate whether the observed apoptosis in HPV-16 E7 expressing cells
upon growth factor withdrawal involves the transcriptional activation of the otherwise
inactive p53.
A cDNA array containing a total of 12 known p53 target genes was analyzed
using probes derived from mRNAs isolated from control and HPV-16 E7 expressing cells
in the presence and absence of growth factors. None of these 12 genes was expressed at a
significantly higher level in growth factor deprived HPV-16 E7 expressing cells,
including the two proapoptotic genes bax and DR5, although the basal level of expression
of these genes varied (Fig. 20). As expected PCNA, a marker of proliferation, was
upregulated by HPV E7 expressing cells (Cheng et al., 1995).
Figure 20:  Expression analysis of a set of p53 responsive genes by transcriptional profiling. A “Human
Apoptosis ATLAS” cDNA nylon array (Clontech) containing 12 p53 responsive genes was analyzed by
sequential hybridization with 32P-labeled single stranded cDNA probes. PCNA is a known HPV-16 E7-
responsive gene and was used as a positive control.
Taken together these findings indicate that p53 is not activated as a transcription
factor during HPV-16 E7 mediated apoptosis upon growth factor withdrawal.
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4.2.1.4 The “trophic sentinel” response upon growth factor withdrawal depends on p53.
It was shown previously that the coexpression of HPV-16 E6 with HPV-16 E7
abolishes E7 mediated apoptosis upon growth factor withdrawal. Since expression of
HPV-16 E6 results in the degradation of p53 it was concluded that HPV-16 E7 mediated
apoptosis is p53 dependent. The observation that neither the DNA binding activity of p53
nor its phosphorylation status is changed and no p53 responsive genes are expressed at
higher levels upon growth factor withdrawal does not support this model. This lead us to
investigate whether HPV-16 E7 mediated apoptosis is independent of p53 as a
transcription factor or whether transcription-independent mechanisms may be involved.
Stable HPV-16 E7 expressing IMR90 cell lines were generated, coexpressing either a
carboxyl terminal truncation-mutant of p53 (p53DD) or HPV-16 E6. p53DD which lacks
the transactivation domain interacts with wild type p53 and thereby results in the
formation of transcriptionally inert tetramers. Hence p53DD acts as a dominant negative
mutant at least with respect to transcription but may not affect other, non-transcriptional
functions of p53. The expression of HPV-16 E6 results in the degradation of p53 and
abolishes p53-mediated transcriptional and non-transcriptional functions. The stable
IMR90 cell lines (LX, E6, E7, p53DD, E6E7 and p53DDE7) were deprived of growth
factors and p53, p21CIP1 and HPV-16 E7 protein levels were determined by immunoblot.
The expression of HPV-16 E6 (E6) results in a decrease of p53 steady state levels, while
the expression of p53DD increases the steady state levels. The expression of either
proteins result in an inhibition of the transcriptional activity of p53, as was determined by
investigating the steady state levels of the p53 target gene p21CIP1. The expression levels
of HPV-16 E7 are shown as well and seems to be lower in cells co-expressing HPV-16
E6 (E6E7) or p53DD (p53DDE7). Steady state levels of p53 or p21CIP1 are not elevated
in any of these cell lines upon growth factor deprivation (Fig. 21A).
Next, the different IMR90 cell populations were grown in the absence of growth
factors and apoptosis was determined by two independent methods. Staining of nuclear
DNA with the dye Hoechst 33258 visualizes nuclear changes like chromatin
condensation while the DNA fragmentation assay quantitates the fragmentation of the
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Figure 21:  HPV-16 E7 mediated apoptosis is inhibited by coexpression of HPV-16 E6 or a dominant
negative truncation mutant of p53 (p53DD). (A) IMR90 cells stably expressing empty vector (LX), HPV-
16 E6 (E6), HPV-16 E7 (E7), a dominant negative C-terminal p53 fragment (p53DD) or HPV-16 E7
together with either HPV-16 E6 (E6E7) or p53DD (p53DDE7) were generated. These cell lines were either
maintained in normal medium (10%) or deprived of growth factors (0%) and the protein levels of p53,
p21CIP1 and HPV-16 E7 levels were determined by immunoblot analysis. The protein expression levels of
GAPDH were used as a loading control. (B) The different IMR90 cell lines were deprived of growth
factors and apoptosis rates were determined by Hoechst staining. The background apoptosis rate in the
presence of growth factors was between 0 and 0.5% in all cell lines. The relative apoptosis was determined
by setting the amount of apoptosis observed in control cells upon growth factor withdrawal as the 0
baseline and comparing the apoptosis rates upon growth factor withdrawal of the other cell lines to that
baseline. The shown results represent the mean of 3 independent experiments. (C) The apoptosis rates of
the different IMR90 cell lines upon growth factor deprivation were determined by using a quantitative
DNA fragmentation assay. The fold increase in DNA fragmentation of each cell line was determined by
comparison of the amount DNA fragmentation in response to growth factor withdrawal to the amount of
background DNA fragmentation in proliferating cells (0-0.2 %). The relative increase in DNA
fragmentation was determined by setting the DNA fragmentation observed in control cells upon growth
factor withdrawal as the 0 baseline and graphing the DNA fragmentation of the other cell lines relative to
this baseline. The data represent the mean of 4 independent experiments.
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chromosomal DNA to nucleosome-sized pieces. Both, nuclear condensation and
nucleosomal DNA fragmentation are hallmarks of apoptotic cells (Kerr et al., 1972;
Oberhammer et al., 1993; Wyllie, 1980). As expected HPV-16 E7 expressing cells show
elevated levels of apoptosis. Cells expressing HPV-16 E6 or p53DD alone have similar
apoptosis and DNA fragmentation levels as growth factor deprived control cells (Fig.
21B,C). Coexpression of either HPV-16 E6 or p53DD can each abrogate the HPV-16 E7
mediated apoptotic response (Fig. 21B,C). This indicates that, although p53 is not active
as a transcription factor, as determined by gene expression profiling (Fig. 20), it is
necessary for HPV-16 E7 mediated apoptosis upon growth factor withdrawal.
4.2.2 Changes in gene expression of HPV-16 E7 expressing cells undergoing
apoptosis.
Gene expression profiling was performed using a cDNA array membrane (Human
Apoptosis ATLAS cDNA array, Clontech) containing 205 different apoptosis related
genes including tumor necrosis factor alpha (TNF-a ), TNF related apoptosis inducing
ligand (TRAIL), TNF-a  receptor 1 (TNFR1), caspases and Bcl-2 family members. Only
two of the 205 monitored genes were upregulated more that 2 fold in HPV-16 E7
expressing genes compared to control cells. Neither of these are known p53 responsive
genes. The finding that the expression levels of both genes were upregulated even further
in HPV-16 E7 expressing cells upon growth factor deprivation indicated their possible
involvement in HPV-16 E7 mediated apoptosis. These two genes are insulin-like growth
factor binding proteins (IGFBPs) 2 and 5. They are secreted proteins that regulate the
availability of the survival factor Insulin-like growth factor (IGF-I) (reviewed in Binoux,
1996) to its receptor and thereby may have an impact on the "trophic sentinel" response.
4.2.2.1 Insulin-like growth factor binding proteins (IGFBPs) -2 and -5 are upregulated
during HPV-16 E7 mediated apoptosis upon growth factor withdrawal.
Upregulation of IGFBP-2 and –5 gene expression was observed in proliferating
HPV-16 E7 expressing cells compared to control cells. IGFBP-3, a p53 responsive
protein that has been implicated in negatively regulating the ability of IGF-I to its
receptor and thereby inhibiting its growth promoting properties (Rajah et al., 1997) was
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Figure 22:  Gene expression and protein levels of Insulin-like growth factor binding proteins (IGFBPs) in
control (LX) and HPV-16 E7 (E7) expressing IMR90 cells upon growth factor withdrawal. (A) Expression
analysis of five IGFBP genes by transcriptional profiling. A “Human Apoptosis ATLAS” cDNA nylon
array (Clontech) was analyzed by sequential hybridization with 32P-labeled single stranded cDNA probes.
(B) Immunoblot analyses of IGFBP 1-6 in control (LX) and HPV-16 E7 expressing IMR90 cells upon
growth factor deprivation. The protein expression levels of GAPDH were used as a loading control.
reported to be bound and inhibited by HPV-E7 (Mannhardt et al., 2000). However
IGFBP-3 was not found to be upregulated in proliferating HPV-16 E7 expressing cells
compared to control cells and its expression level upon growth factor deprivation did not
change whereas the gene expression levels of IGFBP-2 and –5 increase even further in
HPV-16 E7 expressing cells upon growth factor withdrawal (Fig. 22A). Immunoblot
analyses were consistent with the gene expression profiling results showing that IGFBP-2
and –5 are upregulated in HPV-16 E7 expressing cells and that their expression is even
further elevated upon growth factor deprivation (Fig. 22B). The gene expression levels as
well as the protein levels of other known IGFBPs were investigated as well, but only
IGFBP-2 and –5 were observed to be upregulated upon growth factor deprivation in
HPV-16 E7 expressing cells (Fig. 22A,B).
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4.2.2.2 The upregulation of IGFBP-2 and IGFBP-5 are dependent of p53
To investigate whether this upregulation of IGFBP-2 and-5 is dependent on p53,
the HPV-16 E7 expressing IMR90 cell lines that co-express either HPV-16 E6 or p53DD
were deprived of growth factors and the protein levels of IGFBP-2 and –5 were
determined by immunoblot. The expression of IGFBP-2 and –5 is upregulated to a
comparable extent in all cell lines expressing HPV-16 E7 independent of the
coexpression of HPV-16 E6 or p53DD. Interestingly, the expression levels of IGFBP-2
and –5 are only further elevated in apoptotic HPV-16 E7 expressing cells while the
protein levels remain almost unchanged in all other cell lines upon growth factor
withdrawal (Fig. 23). This indicates that the upregulation of IGFBP-2 and –5 may be
dependent on p53 to some extent, although it remains to be elucidated whether increased
expression of these proteins mechanistically contributes to the induction of apoptosis.
The fact that HPV-16 E7 expression in the E6 or p53DD coexpressing cells is lower
correlates with the decreased expression of IGFBP-2 and –5 in these cells.
Figure 23:  IGFBP-2 and IGFBP-5 protein levels are upregulated in apoptotic HPV-16 E7 expressing
IMR90 cells. IMR90 cells stably expressing empty vector (LX), HPV-16 E6 (E6), HPV-16 E7 (E7), a
dominant negative C-terminal fragment of p53 (p53DD) or HPV-16 E7 together with either HPV-16 E6
(E6E7) or p53DD (p53DDE7) were deprived of growth factors. IGFBP-2 and IGFBP-5 protein levels were
determined by immunoblot analysis. The co-expression of HPV-16 E6 or a dominant negative mutant of
p53 (p53DD) with HPV-16 E7 abolished the upregulation of IGFBP-2 and -5 protein levels upon growth
factor deprivation. The protein expression levels of GAPDH were used as a loading control.
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4.2.2.3 NF k B is activated in HPV-16 E7 expressing cells upon growth factor
withdrawal.
NF k B is a transcription factor that can exhibit pro- as well as anti-apoptotic
activities. It was reported that the IGFBP-2 gene has a NFk B binding site in its promoter
(Cazals et al., 1999). Since elevation of IGFBP-2 is observed, we investigated whether
the transcription factor NFk B is activated upon the induction of apoptosis in HPV-16 E7
expressing IMR90 cells upon growth factor withdrawal. An EMSA was performed and it
was observed that the DNA binding activity of NF k B is increased in apoptotic HPV-16
E7 expressing IMR90 cells (Fig. 24). This indicates that the activation of NFk B
correlates with the induction of IGFBP-2 in these cells. Since NF k B can exhibit pro- as
well as anti-apoptotic functions, it has to be further elucidated whether NFk B activation
enhances or delays the observed apoptosis.
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Figure 24:  The activity of NF k B is elevated in HPV-16 E7 expressing cells upon growth factor
deprivation. Control and HPV-16 E7 expressing IMR90 cells were deprived of growth factors. The DNA
binding activity of NF k B was determined using Electrophoretic Mobility Shift Assay (EMSA). U2OS cells
transfected with the NF k B subunits p50 and p65 were used as positive controls. The NFk B/oligonucleotide
(NF k B) complexes were identified by supershift analysis using a -p50 and a- p65 antibodies.
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4.2.3 The involvement of known apoptotic pathways in HPV-16 E7 mediated
apoptosis
1.1.1.1 The involvement of the caspase cascade in HPV-16 E7 mediated apoptosis upon
growth factor withdrawal.
Caspases are mediators of apoptosis (Enari et al., 1998; Green and Kroemer,
1998). The activity of different caspases (caspase 3 and 8) were therefore determined in
HPV-16 E7 expressing cells upon growth factor withdrawal. ApoAlert Fluorometric
caspase activity assay kits (Clontech), which measure the specific activity of caspase 3
and caspase 8, were used. It was observed that the specific activity of caspase 8 remained
Figure 25: Activity levels of caspase 8 (C8) and caspase 3 (C3) in control (LX) and HPV-16 E7 expressing
cells upon growth factor withdrawal. Control (LX) and HPV-16 E7 expressing IMR90 cells were deprived
of growth factors and caspase 8 activity was determined using the ApoAlert Caspase 8 Fluorescence Assay
kit. The addition of the specific caspase 8 inhibitor IETD-fmk was used to prove the specificity of the
reaction. Control (LX) cells treated with TNF-a  were used as a positive control. Caspase 3 activity of the
same cells was determined using the ApoAlert Caspase 3 Fluorescence Assay kit. The addition of the
specific caspase 3 inhibitor DEVD-CHO was used to guarantee the specificity of the reaction. Control (LX)
cells treated with TNF-a and cycloheximide were used as a positive control.
flu
o
re
sce
n
ce
  u
n
its
fl
u
o
re
sc
e
n
ce
 u
n
it
s
C8
LXLX E7
C3
LX E7 LX
0
450
900
1350
1800
0
2000
4000
6000
8000
10000
12000
Results                                                                                                                                                                   56
unchanged during HPV-16 E7 mediated apoptosis upon growth factor withdrawal, while
the specific activity of caspase 3 was increased (Fig. 25). This indicates that caspase 3 is
activated through caspase 8 independent mechanisms. Caspase 8 activity is mostly
regulated by death receptors such as the TNF receptor (TNFR), while caspase 3, a
downstream effector caspase, can be activated by caspase 8 and 9. Control IMR90 cells
that were treated with TNF-a  served as a positive control for caspase 8 and caspase 3
activity.
4.2.3.2 Cytochrome c release in HPV-16 E7 mediated apoptosis upon growth factor
withdrawal.
The finding that caspase 3 was activated while the activity of caspase 8 remained
unchanged indicated that the mitochondria, which signal upstream of caspase 3 and do
not necessarily receive their signals through caspase 8, might be involved. To investigate
the possible role of the mitochondria in HPV-16 E7 mediated apoptosis upon growth
factor withdrawal, HPV-16 E7 expressing cells and control cells were deprived of growth
factors and subjected to subcellular fractionation. Untreated and taxol-treated MCF-7
cells were used as a positive control (Kottke et al., 2002). The release of cytochrome c
from the mitochondria was determined by measuring the cytochrome c contents of the
mitochondrial and the cytoplasmic fraction using a human cytochrome c detection ELISA
kit (Quantikine, R&D systems). The ratio of cytochrome c content of mitochondrial to
cytoplasmic fraction of proliferating and growth factor deprived control and E7
expressing cells was determined. After setting the cytochrome c release of proliferating
control and HPV-16 E7 expressing cells and untreated MCF-7 cells as zero-baseline, the
differences in cytochrome c distribution were graphed. An increase in cytochrome c in
the cytoplasmic fraction was observed in growth factor deprived HPV-16 E7 expressing
cells (Fig. 26). These results correlate with the activation of caspase 3 (Fig. 25).
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Figure 26:  Cytochrome c release from the mitochondria in HPV-16 E7 expressing IMR90 cells upon
growth factor deprivation. Control (LX) and HPV-16 E7 expressing cells (E7) were deprived of growth
factors and subsequently subjected to subcellular fractionation. Untreated and taxol-treated MCF-7 cells
were used as controls. The cytochrome c content of the mitochondrial and the cytoplasmic fraction was
determined using the Quantikine human cytochrome c ELISA kit (R&D systems). The cytochrome c
content of the cytoplasmic fraction was determined by normalizing it to the cytochrome c content of the
mitochondrial fraction. Subsequently the cytochrome c contents in the cytoplasmic fraction of proliferating
control and HPV-16 E7 expressing cells as well as untreated MCF-7 cells were set as zero baseline and the
relative cytochrome c release upon growth factor deprivation or taxol-treatment was determined according
to this baseline and graphed.
4.2.3.3 Translocation of AIF from the mitochondria to the nucleus in apoptotic HPV-16
E7 expressing cells
It was previously shown that the apoptosis inducing factor (AIF) is released from
the mitochondria and translocates to the nucleus where it exhibits nuclease activity and
results in DNA fragmentation (Susin et al., 1999). To investigate whether AIF is involved
in HPV-16 E7 mediated apoptosis upon growth factor deprivation immunofluorescence
analyses were performed. The human Tid-1 gene encodes two alternatively spliced
mitochondrial proteins (Syken et al., 1999) that are not released from the mitochondria
during apoptosis (unpublished data) and were used as controls for mitochondrial
localization. AIF colocalizes with hTid-1 proteins in proliferating control and HPV-16 E7
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Figure 27:  Localization of the apoptosis-inducing factor (AIF) in proliferating and growth factor deprived
control (LX) and HPV-16 E7 expressing cells. Control and HPV-16 E7 expressing cells were deprived of
growth factors and localization of AIF and the mitochondrial hTid-1 proteins (Tid) were determined by
immunofluorescence. Nuclei were visualized by Hoechst 33258 staining.
expressing cells (Fig. 27). This colocalization of AIF with hTid-1 was also observed in
growth factor deprived control and HPV-16 E7 expressing cells. This finding shows that
AIF does not translocate to the nucleus in HPV-16 E7 expressing cells upon growth
factor deprivation (Fig. 27) and indicates that it is not involved in HPV-16 E7 mediated
apoptosis.
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5. Discussion
5.1 Stabilization and functional impairment of the tumor suppressor
p53 by the human papillomavirus type 16 E7 oncoprotein
5.1.1 Functional impairment of the tumor suppressor p53 by the HPV-16 E7
oncoprotein
In normal cells, stabilization of p53 is generally observed in response to genotoxic
insults. Under these conditions, p53 stabilization leads to a corresponding increase of its
transcriptional activation potential and transcriptional induction of downstream target
genes (reviewed in Meek, 1999). Many of these genes encode growth suppressive or
cytotoxic proteins, and consequently, activation of p53 generally leads to growth arrest or
apoptosis (reviewed in Levine, 1997). In contrast, IMR90 cells stably expressing HPV-16
E7 grow rapidly in the presence of elevated p53 levels. The rate of spontaneous apoptosis
in these cells is similar to control cells. Previous work has indicated that expression of
HPV-16 E7, while it mimics a p53-dependent DNA damage response, does not fully
activate p53 (Jones et al., 1999). Most dramatically, p21CIP1 protein but not mRNA levels
are increased in E7 expressing cells (see Fig. 10, 9B) consistent with an effect on protein
stabilization rather than p53-dependent transcriptional induction (Jones et al., 1999).
Hence we analyzed in more detail whether the stabilized p53 in HPV-16 E7 expressing
cells is activated as a transcription factor. Analysis of the transcriptional activity of an
artificial p53-responsive reporter construct in a matched pair of control and HPV-16 E7
expressing IMR90 cells suggested that, despite the higher steady state levels (Fig. 8,10)
the transcriptional activity of p53 was decreased in HPV-16 E7 expressing cells (Fig.
9A). Consistent with these findings, transcriptional profiling of matched control and
HPV-16 E7 expressing cells showed no marked increases in the mRNA levels of any of
the known p53-responsive genes present on this array (Fig. 9B). Similarly, immunoblot
analyses showed that levels of the pro-apoptotic p53 targets bax (Miyashita and Reed,
1995) and DR5 (alias TRAIL-R2/Apo2/Killer) (Wu et al., 1997) were not increased in
rapidly growing HPV-16 E7 expressing IMR90 cells (Fig. 10). The decreased activity of
the p53 responsive luciferase reporter (Fig. 9A) appears to be at variance with the
unchanged levels of p53 target genes as determined by transcriptional profiling (Fig. 9B)
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and may suggest that other transcriptional elements are also involved in regulating the
expression of these genes. Regardless, our results demonstrate that expression of HPV-16
E7 results in stabilization of the protein but not activation of p53.
The mechanisms that lead to p53 stabilization in response to HPV-16 E7
expression appear different from those involved in DNA damage. Our findings suggest
that posttranslational modifications such as phosphorylation and/or acetylation events
that are necessary to trigger transcriptional activation of the stabilized p53 are not
induced by HPV-16 E7 expression. Alternatively, HPV-16 E7 may interfere with the
transcriptional activation of p53. This has been suggested by earlier studies
demonstrating that the expression of HPV-16 E7 could interfere with p53-dependent
activation of reporter plasmids in transient assays. These experiments suggested that the
ability of HPV-16 E7 to interfere with p53-mediated transcriptional activation might
correlate with the capacity of HPV-16 E7 to interact with TATA-box binding protein,
TBP (Massimi and Banks, 1997). Additional studies will be necessary to further address
these issues. To determine whether HPV-16 E7 interferes with the transcriptional
activation of p53, its effects on exogenous p53 were investigated. Reporter assays with
increasing amounts of exogenous p53 were performed in a matched pair of control and
HPV-16 E7 expressing IMR90 cells using an artificial p53 responsive reporter construct.
These studies showed that exogenous p53 is transcriptionally active in HPV-16 E7
expressing cells while the transcriptional activity of endogenous p53 is impaired by the
expression of HPV-16 E7 (Fig. 11). This indicates that the transcriptional inactivation of
p53 by HPV-16 E7 might be a “long term” effect and therefore may not be observed in
transiently transfected cells. Similarly the stabilization of p53 by HPV-16 E7 could never
be observed in transient assays. This may indicate that the stabilization and
transcriptional inactivation of p53 by HPV-16 E7 might be linked. Further experiments
will be necessary to further illuminate this mechanism.
5.1.2 Susceptibility of p53 to mdm2 mediated degradation in HPV-16 E7
expressing IMR90 cells
In normal cells p53 stabilization is due to phosphorylation which inhibits mdm2
mediated degradation. The ubiquitin ligase mdm2 is a transcriptional target of p53 and is
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thought to play a role as a feedback regulator to keep p53 activity in check (Wu et al.,
1993). During carcinogenic progression of high-risk HPV infected cells p53 is targeted
for proteasomal degradation by a complex of the HPV-16 E6 oncoprotein the ubiquitin
ligase E6-AP (Scheffner et al., 1993; Scheffner et al., 1995). Furthermore, it has been
reported that mdm2 mediated p53 degradation is completely abrogated in HPV-positive
cervical cancer cells and critically depends on E6/E6-AP (Hengstermann et al., 2001).
Given the fact that the only other viral protein consistently expressed in cervical cancer
cells is HPV E7 it is thus conceivable that HPV-16 E7 is responsible for blocking mdm2-
mediated p53 degradation in these cells.
Other oncoproteins including SV40 TAg (Tiemann and Deppert, 1994), Ad E1A
(Lowe and Ruley, 1993), and c-myc (Hermeking and Eick, 1994) can stabilize p53. Since
each of these oncoproteins results in dysregulation the G1/S transition it is plausible that
aberrant activation of the pRB-regulated transcription factor E2F may cause p53
stabilization. One potential mechanistic link between E2F activation and p53 stabilization
was suggested by the finding that p14ARF, an inhibitor of mdm2-mediated p53
degradation (Zhang et al., 1998) was E2F responsive (Bates et al., 1998), and its cellular
levels increased in response to Ad E1A and c-myc expression (de Stanchina et al., 1998;
Zindy et al., 1998). Surprisingly, however, p14ARF levels do not increase upon HPV-16
E7 expression, and HPV-16 E7 mediated p53 stabilization was observed in mouse
embryo fibroblasts deficient of the murine homolog of p14ARF, p19ARF (Seavey et al.,
1999). Hence other pathways must exist that can interfere with either the ability of mdm2
to ubiquitinate p53 or the process of proteasomal p53 degradation.
A previous study reported increased transcription from the p53 responsive mdm2
promoter P2 in HPV-16 E7 expressing cells (Seavey et al., 1999). Our analysis did not
reveal any evidence for increased mdm2 mRNA expression in HPV-16 E7 expressing
cells (Fig. 9B). Consistent with this, mdm2 protein levels were only slightly increased in
HPV-16 E7 expressing cells (Fig. 12A). Hence we measured the transcriptional
activation of a mdm2 P2 promoter driven reporter construct in control and HPV-16 E7
expressing IMR90 cells. Consistent with the results obtained with the artificial p53-
responsive reporter (Fig. 9A), we did not detect increased activation of this reporter in
HPV-16 E7 expressing cells, in fact, the transcriptional activity of the mdm2 P2 promoter
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construct was decreased in HPV-16 E7 expressing cells (Fig. 12B). This supports the
finding that the stabilized p53 is not transcriptionally active in HPV-16 E7 expressing
cells without additional stimuli such as DNA damage, as was shown using gene
expression profiling (Fig. 9B), transient reporter assays (Fig. 9A) and immunoblot
analyses (Fig. 10). To investigate whether HPV-16 E7 inhibits the interaction of mdm2
and p53 or blocks the degradation of mdm2/p53 complexes, co-immunoprecipitation
studies were performed. Our analyses revealed no evidence for a disruption of the
mdm2/p53 interaction in normal or HPV-16 E7 expressing cells (Fig. 12A), suggesting
that the interaction of mdm2 and p53 is not generally impaired in HPV-16 E7 expressing
cells. This is in contrast to a previous study where mdm2 and p53 interaction was
dramatically reduced in the presence of HPV-16 E7 (Seavey et al., 1999). The two
studies were performed with different strains of diploid normal human fibroblasts and it
is of note that in the IMR90 cells used in this study, we did not observe a dramatic
upregulation of mdm2 expression in HPV-16 E7 expressing cells (Fig. 9B, 12A)
suggesting that either there are differences in the expression levels of HPV-16 E7 in the
two studies or, that there may be differences in the susceptibility to p53 stabilization and
activation between these strains of human fibroblasts. The finding that mdm2 is bound to
p53 in HPV-16 E7 expressing IMR90 cells correlates with the finding that the stabilized
p53 is not transcriptionally active since mdm2 binds to the transactivation domain of p53.
Interestingly, however, our experiments revealed that the stabilized p53 in HPV-16 E7
expressing cells remains susceptible to proteasomal degradation by exogenous mdm2 as
well as by the HPV-16 E6/E6-AP complex (Fig. 13). Additional studies will be necessary
to delineate whether E7 interferes with mdm2-mediated ubiquitination of p53, or whether
HPV-16 E7 affects the turnover of ubiquitinated p53.
Interestingly, mdmX a homologue of mdm2 that may act as a dominant negative
inhibitor of mdm2 has been described. MdmX can bind p53 and stabilize it by preventing
mdm2-mediated degradation through the proteasome (Jackson and Berberich, 2000;
Sharp et al., 1999). MdmX bound p53 was reported to be transcriptionally inactive
(Shvarts et al., 1997). These results suggest that mdmX may be an attractive candidate to
act as a mediator of p53 stabilization in the presence of HPV-16 E7. Preliminary analyses
revealed a 1.4 fold increase in mdmX mRNA levels in HPV-16 E7 expressing cells (Fig.
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12C). Due to antibody limitations it could not be determined whether mdmX or a related
protein may be present at higher levels in HPV-16 E7 expressing cells and may
contribute to p53 stabilization in HPV-16 E7 expressing IMR90 cells.
5.1.3 Stabilization of the tumor suppressor p53 by the HPV-16 E7 oncoprotein
Stabilization and inactivation of p53 can occur through different mechanisms and it
was important to investigate how HPV-16 E7 mediates the observed p53 stabilization and
inactivation. It has been reported that wild-type p53 can be functionally inactivated by
nuclear exclusion. This has been documented in different carcinomas (Bosari et al., 1995;
Moll et al., 1995; Moll et al., 1992; Schlamp et al., 1997; Ueda et al., 1995), and in
addition, some viral oncoprotein proteins such as the Ad E1B-55kDa protein and the
hepatitis B virus X protein can mislocalize p53 to the cytoplasm, thereby inhibiting its
transcriptional activities (Elmore et al., 1997; van den Heuvel et al., 1993). However,
subcellular fractionation studies showed that p53 in HPV-16 E7 expressing cells remains
nuclear (Fig. 16,13). In some instances, p53 protein, which assumes a mutant
conformation is stabilized. This was observed in many cancers that contain a p53 with a
point mutation in its DNA binding domain (Cho et al., 1994; Pavletich et al., 1993).
These point mutations oftentimes produce a change in the global conformation of the
protein which can be monitored by a set of antibodies that recognize conformational
epitopes (Gannon et al., 1990; Milner et al., 1987). Immunoprecipitation studies with
these conformation specific antibodies (Fig. 15A) as well as treatment with
geldanamycin, a compound that disrupts mutant p53/hsp90 complexes (Fig. 15B),
demonstrated that the stabilized p53 in HPV-16 E7 expressing cells remains in a wild-
type conformation. As mentioned earlier the phosphorylation of p53 at specific amino
acid residues results in its stabilization. An analysis of the phosphorylation state of p53
by two-dimensional gel electrophoresis displayed no major differences in the number of
phospho-forms in control or HPV-16 E7 expressing cells (Fig. 14). Taken together these
results show that the p53 in HPV-16 E7 expressing cells is in the normal compartment of
the cell, maintains a wild type conformation and can still bind to mdm2. Treatment of
HPV-16 E7 expressing cells with the nuclear export inhibitor leptomycin B led to a
further increase in p53 steady state levels, demonstrating that nuclear export of p53 is not
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generally abrogated in HPV-16 E7 expressing cells (Fig. 17). The observation that p53
can be exported from the nucleus indicates that the stabilization might be due to an
impairment of p53 degradation. This was investigated by treatment of control and HPV-
16 E7 expressing cells with the proteasome inhibitor lactacystin. However, similar to the
nuclear export inhibitor leptomycin B, lactacystin treatment resulted in increased p53
levels in normal and HPV-16 E7 expressing cells. These results suggest that proteasomal
p53 degradation is not completely blocked in HPV-16 E7 expressing cells (Fig. 17).
Another possibility is that HPV-16 E7 may interfere with a step that involves recognition
of ubiquitinated forms of p53 by the proteasome. This process has not yet been studied in
great detail, however, it has been postulated that ubiquitin binding proteins such as
hPLIC that are associated with the proteasome may play a role in this process (Kleijnen
et al., 2000). Further experiments are necessary to investigate this hypothesis.
5.2 The “trophic sentinel” response of HPV-16 E7 expressing cells
upon growth factor withdrawal
5.2.1 Involvement of the tumor suppressor p53 in the “trophic sentinel” response
of HPV-16 E7 expressing cells
Cells expressing oncogenes such as HPV-16 E7 are predisposed to apoptosis upon
suboptimal growth conditions (Jones et al., 1997b). It is not clear, however, whether this
“trophic sentinel” response is mediated by p53. The involvement of p53 in most other
apoptotic responses, such as upon DNA damage, is well established, but the “trophic
sentinel” response is not as well studied as the “DNA damage sentinel” response. It was
shown previously that coexpression of HPV-16 E6 abrogates the HPV-16 E7 mediated
apoptosis upon growth factor deprivation (Jones et al., 1997b). This indicates that this
apoptosis response might be p53 dependent. We previously showed that the stabilized
p53 in HPV-16 E7 expressing cells is transcriptionally inert in proliferating cells. Since
p53 can mediate apoptosis through transcription-dependent and –independent pathways,
the possible transcriptional involvement of p53 in the ”trophic sentinel” response was
determined. In order to become active as a transcription factor upon different stimuli p53
has to be stabilized and activated by posttranslational modifications such as
phosphorylation. Therefore the phosphorylation of p53 at known residues was
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investigated using phosphospecific antibodies. This analysis revealed no differences in
the phosphorylation status of p53 in proliferating or apoptotic HPV-16 E7 expressing
cells (Fig. 18). The observation that the phosphorylation status of p53 in control (LX) and
HPV-16 E7 expressing cells (E7) in the presence of growth factors is unchanged (Fig. 18)
is consistent with the finding that the number of phospho-forms observed in these cells by
two-dimensional gel electrophoresis were unchanged (Fig. 14). These phospho-forms
very likely represent phosphorylations at amino acid residues different than those
investigated by phosphospecific antibodies. To investigate whether p53 in HPV-16 E7
expressing cells is capable of binding to its consensus sequence, a p53 EMSA was
performed. The observation that the stabilized p53 in proliferating HPV-16 E7 expressing
cells can bind to its DNA consensus sequence (Fig. 19) was somewhat surprising since it
is not transcriptionally active (Fig. 9A,B, 10). This indicates that HPV-16 E7 might
interfere with the assembly of the transcription initiation complex rather than impairing
the DNA binding capacity of the stabilized p53. Further experiments including chromatin
immunoprecipitations will be necessary to illuminate this mechanism. The finding that
the DNA binding capacity of p53 is neither enhanced in HPV-16 E7 expressing cells nor
in control cells upon growth factor deprivation (Fig. 19) indicates that its DNA binding
activity is not increased during HPV-16 E7 mediated apoptosis. This correlates with the
finding that p53 is not phosphorylated at the investigated serine residues in apoptotic
HPV-16 E7 expressing cells (Fig. 18). In addition, analysis of known p53 target genes
did not reveal an increase in the transcriptional activity of p53 in HPV-16 E7 mediated
apoptosis upon growth factor withdrawal (Fig. 20). This cDNA array did not include the
genes PERP, Noxa or p53AIP1, which were reported to be involved in p53 mediated
apoptosis (Attardi et al., 2000; Oda et al., 2000a; Oda et al., 2000b), and the possibility
remains that these factors might be involved in mediating HPV-16 E7 dependent
apoptosis upon growth factor withdrawal.
Since p53 may induce apoptosis through transcription-independent mechanisms
as well (Bennett et al., 1998; Ding et al., 2000; Yan et al., 1997), we investigated
whether the observed HPV-16 E7 mediated cell death in response to growth factor
deprivation is independent of p53 or whether transcription-independent mechanisms are
involved. Surprisingly, transcriptional inactivation by a dominant negative p53 mutant as
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well as HPV E6 induced degradation of p53 (Fig. 21A) abrogated HPV-16 E7 dependent
apoptosis (Fig. 21B,C). This shows that HPV-16 E7 mediated apoptosis upon growth
factor withdrawal differs from c-myc induced apoptosis in growth factor deprived cells.
The c-myc induced apoptotic response was shown to be independent of p53 taking the
same approach by coexpressing the carboxyl terminal p53 fragment (p53DD) that acts as
a dominant negative mutant (Juin et al., 1999). This indicates that the transcriptional
activity of p53 is necessary for HPV-16 E7 mediated apoptosis (Fig. 28) although none of
the investigated target genes are induced nor are any of the investigated serine residues
on p53 are phosphorylated. This finding may indicate that p53 is transcriptionally
activated by either phosphorylation of other, not investigated residues or is subject to
other posttranslational modifications in apoptotic HPV-16 E7 expressing IMR90 cells. It
is also a possibility that the dominant negative carboxyl terminal fragment of p53 alters
the conformation of the transcriptionally inactive p53 heterotetramers and thereby
abolishes transcription-independent mechanisms as well. It has been reported that the p53
homologes p63 and p73, are required for p53 dependent apoptosis in response to DNA
damage (Flores et al., 2002). Some mutant forms of p53 that act in a dominant negative
fashion can interact with p63 and p73 (reviewed in Moll et al., 2001). It is therefore
possible that p63 or p73 functions are altered by the dominant negative mutant p53 used
and may contribute to the observed apoptosis. Further studies using mouse embryo
fibroblasts (MEFs) where p53, p63 and/or p73 are deleted will be useful to investigate the
role of p53 and related family members in HPV-16 E7 mediated apoptosis.
5.2.2 Unknown mediators of HPV-16 E7 mediated apoptosis upon growth factor
withdrawal
In addition to investigating the gene expression levels of known p53 target genes,
gene expression profiling was used to determine changes in gene expression levels of
genes involved in HPV-16 E7 mediated apoptosis upon growth factor withdrawal. The
used cDNA array membrane contained 205 different genes and although the cDNA array
analysis showed no increase in expression levels of any of the known p53-target genes,
two genes were observed to be upregulated in HPV-16 E7 expressing cells. These two
genes are IGFBP-2 and IGFBP-5. Expression levels of these proteins were further
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increased in apoptotic HPV-16 E7 expressing cells upon growth factor withdrawal (Fig.
22A). This increase was verified by immunoblot (Fig. 22B). Since these proteins are
involved in the regulation of the availability of the survival factor IGF-I (reviewed in
Binoux, 1996), they may play a role in the regulation of the “trophic sentinel” response in
HPV-16 E7 expressing cells (Fig. 28). It is known that in cells overexpressing the c-myc
oncogene, the apoptotic response can be held in check by the addition of survival factors
such as the insulin-like growth factor (IGF-I) (Harrington et al., 1994a). It remains to be
investigated whether this is also the case in HPV-16 E7 mediated apoptosis following
growth factor deprivation. Further experiments using growth media without growth
factors and supplementing it with different growth factors such as IGF-I, insulin,
fibroblast growth factor (FGF) or others, will be performed to determine the role of
different growth factors in HPV-16 E7 mediated apoptosis upon suboptimal growth
conditions. IGFBP-2 and IGFBP-5 were only upregulated in apoptotic HPV-16 E7
expressing cells while the protein levels remained unchanged upon growth factor
deprivation in IMR90 cell lines coexpressing a transcriptionally inactive form of p53
(p53DD) or HPV-16 E6 with HPV-16 E7 (Fig. 23). This indicates that upregulation of
the two IGFBPs during HPV-16 E7 mediated apoptosis is dependent on the
transactivation domain of p53 although it is not transcriptionally active. IGFBP-2 and –5
levels may also be lower in cells coexpressing HPV-16 E6 or p53DD with HPV-16 E7
due to lower HPV-16 E7 protein expression levels. A report showing that the IGFBP-2
gene has NF k B binding sites in its promoter (Cazals et al., 1999) led to the investigation
whether NF k B is activated in apoptotic HPV-16 E7 expressing IMR90 cells. A previous
report indicated crosstalk between the activated transcription factors p53 and NF k B. The
two transcription factors were shown to inhibit each other’s ability to stimulate target
gene expression depending of the apoptotic stimuli (Webster and Perkins, 1999). In
contrast to these findings another study showed that the induction of p53 not only results
in NF k B activation but that p53-dependent apoptosis is abrogated by the loss of
functional NFk B (Ryan et al., 2000). Although the results of these two studies are
contradictory, they indicate that p53 and NFk B signal pathways are somehow connected.
Since the DNA binding activity of NFk B was elevated in HPV-16 E7 expressing IMR90
cells upon growth factor withdrawal (Fig. 24) but the DNA binding activity as well as the
Discussion                                                                                                                                                             68
transcriptional activity of p53 remained unchanged in growth factor deprived cells (Fig.
19, 20). This could indicate that NFk B negatively regulates the transcriptional activity of
p53. On the other hand the two proteins may crosstalk on a non-transcriptional level.
Since NF k B is a transcription factor that exhibits both pro- and antiapoptotic activities, it
is not clear whether it is activated to counteract apoptosis or to enhance it. The same
concern has to be raised about the IGFBPs, which were reported to be pro- or
antiapoptotic. Further experiments using compounds that block activation of NFk B will
provide insight into the role of NFk B activation in HPV-16 E7 mediated apoptosis (Fig.
28).
5.2.3 The involvement of known apoptotic pathways in HPV-16 E7 mediated
apoptosis upon growth factor deprivation
Caspases are cysteine proteases that are activated by proteolytic processing
(Green and Kroemer, 1998). They have the capacity to activate each other, which results
in the initiation of a caspase cascade. The caspase cascade is involved in most apoptotic
responses. The involvement of caspases in the “trophic sentinel” response is not very well
established. Therefore, the activity of the downstream “effector” caspase 3 and the
upstream “initiator” caspases 8 were determined. The activity of caspase 3 was found to
be elevated while caspase 8 was not activated in HPV-16 E7 expressing cells upon
growth factor deprivation. Activation of caspase 3 without activation of caspase 8
suggests the involvement of the mitochondria in the HPV-16 E7 mediated apoptosis. To
investigate whether the mitochondria are involved, cytochrome c release was determined
by measuring the changes of the cytochrome c contents of the mitochondrial and the
cytoplasmic fraction upon growth factor withdrawal. Higher cytochrome c contents were
observed in the cytoplasmic fraction of apoptotic HPV-16 E7 expressing cells, which
correlates with the elevated activity of caspase 3 (Fig. 28).
The apoptosis-inducing factor (AIF) was reported to induce apoptosis in a caspase
independent manner by translocating to the nucleus and inducing DNA fragmentation
(Susin et al., 1999). AIF localization in proliferating and growth factor deprived control
and HPV-16 E7 expressing cells was determined by immunofluorescence. We found that
AIF remains in the mitochondrial fraction in growth factor deprived HPV-16 E7
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expressing cells. This indicates that AIF is not involved in HPV-16 E7 mediated
apoptosis upon growth factor deprivation.
Figure 28:  Model for HPV-16 E7 mediated apoptosis upon growth factor withdrawal. In proliferating cells
results the expression of HPV-16 E7 in the inhibition of differentiation and the promotion of proliferation.
Upon growth factor withdrawal undergo HPV-16 E7 expressing cells apoptosis. The “trophic sentinel”
response in HPV-16 E7 expressing cells induces cytochrome c release from the mitochondria and results in
caspase 3 activation, which triggers apoptosis. The role of p53 in HPV-16 E7 mediated apoptosis is not
clear. P53 is not activated as a transcription factor but is required for apoptosis to ensue. One possibility is
that p53 may counteract the prosurvival function of NFk B. It remains to be elucidated whether the
upregulation of IGFBP-2 and -5 and the activation of NF k B are involved in HPV-16 E7 mediated apoptosis
or whether this represents a cellular attempt to prevent apoptosis and signal survival.
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6. Future directions
The further investigation of the stabilization and functional impairment of p53 by
HPV-16 E7 includes the determination whether HPV-16 E7 can interfere with the
ubiquitination of p53 by mdm2 by investigating the ubiquitination status of the stabilized
p53 compared to control cells. The possible involvement mdmX in the abrogation of
mdm2 mediated p53 degradation can be addressed as soon as better antibodies are
available. The interference of HPV-16 E7 with the recognition of ubiquitinated p53 by
the proteasome or impairment of the turnover of the ubiquitinated p53 could be other
mechanistical possibilities for the stabilization. The finding that the stabilized p53 is
transcriptionally inactive indicates that modifications different from those induced by
DNA damage, may be involved in stabilization. These may include phosphorylations at
residues that were not investigated or acetylation of the carboxyl terminus. The finding
that the stabilized p53 is capable of binding DNA indicates that HPV-16 E7 may interfere
with the assembly of the transcription initiation complex. This can be investigated by
chromatin immunoprecipitation and subsequent identification of the bound components.
Future investigations evaluating the underlying mechanisms of HPV-16 E7
mediated apoptosis upon growth factor withdrawal will focus on the role of the IGFBP-2
and –5. It remains to be elucidated whether upregulation of these two proteins is involved
in the induction of apoptosis or whether it is an antiapoptotic reaction of the cell in
response to suboptimal growth conditions. This question may be addressed by adding
recombinant IGFBP-2 and –5 to the growth media and monitor the apoptosis rates to
observe an enhancement or a decrease in apoptosis rates due to increased exogenous
IGFBP-2 or-5 levels. Alternatively the corresponding cDNAs could be expressed in cells
either in the absence or the presence of HPV-16 E7. Similarly the pro- or antiapoptotic
role of NFk B can be determined by blocking NFk B activation and monitoring apoptosis
rates.
The involvement of p53 in HPV-16 E7 mediated apoptosis could be due to the
transcriptional induction of target genes that were not investigated in this study including
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PERP, Noxa, and p53AIP1. p53 might be subject to other posttranslational modifications
such as acetylation. Another possibility is that a portion of the stabilized p53 may
translocate to the mitochondria and thereby induce an apoptotic response. It is also
possible that the p53 homologes p63 and p73 play a role in HPV-16 E7 mediated
apoptosis. This could be investigated by using MEFs that are wild type or null for p53,
p63 or p73 as well as MEFs missing combinations of two or all three p53 family
members.
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7. Summary
The expression of high-risk HPV-16 E7 in a cell without HPV-16 E6 results in the
degradation of pRB but in the stabilization of p53. This increase is not due to increased
transcription of p53, but results from an extension of its half-life (Jones and Münger,
1997). The data presented in this thesis show that the stabilized p53 in HPV-16 E7
expressing cells is not transcriptionally active in the presence or absence of growth
factors although p53 seems necessary for HPV-16 E7 mediated apoptosis upon growth
factor withdrawal. Furthermore, the stabilized p53 in proliferating HPV-16 E7 expressing
cells can bind mdm2, is in a wild type conformation and is in the normal compartment of
the cell. Nuclear export and proteasomal degradation of p53 are not impaired by HPV-16
E7 and it remains to delineate whether HPV-16 E7 inhibits the assembly of the
transcriptional p53 initiation machinery or the ubiquitination of p53 and thereby
inactivates and stabilizes p53.
It has been shown previously that cells expressing oncogenes such as HPV-16 E7
are predisposed to apoptosis upon suboptimal growth conditions. Investigations of the
mechanisms underlying HPV-16 E7 mediated apoptosis upon growth factor withdrawal
revealed the involvement of the mitochondria as demonstrated by cytochrome c release
and caspase 3 activation. The apoptosis-inducing factor (AIF) remained mitochondrial
and is not involved in mediating apoptosis in HPV-16 E7 expressing cells. An
upregulation of IGFBP-2 and IGFBP-5 was observed in HPV-16 E7 expressing cells with
a further increase in protein levels upon suboptimal growth conditions. These proteins
have been shown to bind and control the cellular availability of the survival factor IGF-I.
It remains to be determined whether the expression of these two proteins predisposes
HPV-16 E7 expressing cells to apoptosis or whether the upregulation is an antiapoptotic
mechanism triggered by the cell in response to deprivation of growth factors.
These results contribute to the better understanding of how cells react to
deregulation of the cell cycle and uncontrolled proliferation induced by viral
oncoproteins. Detailed knowledge about the effect of HPV-16 E7 in proliferating cells as
well as growth factor deprived cells may lead to the development of a novel treatment for
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HPV-positive cancers by rendering the cells susceptible to HPV-16 E7 mediated
apoptosis.
Keywords: tumor supressor p53, Human papillomavirus type 16 E7 oncoprotein,
apoptosis
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